UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐ Preliminary Proxy Statement
☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☒ Definitive Proxy Statement
☐ Definitive Additional Materials
☐ Soliciting Material Pursuant to §240.14a-12
EyePoint Pharmaceuticals, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
☒ No fee required
☐ Fee paid previously with preliminary materials
☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
|
| ||
|
|
| ||
480 Pleasant Street, Suite C400 Watertown, MA 02472 United States |
|
| ||
|
|
| ||
April To Our Stockholders,
| retinal diseases. We completed our transformation into a clinical-stage biopharmaceutical company with the out-license of the YUTIQ® franchise, and now we are | |||
| We are focused on advancing and expanding our pipeline of innovative sustained-delivery treatments to provide a brighter future for those at risk of losing their sight. | |||
EyePoint’s bioerodible Durasert E™ drug delivery technology provides a best-in-class sustained release intravitreal insert for treating serious retinal diseases. This technology enables a constant, sustained drug release known as zero order kinetics. We have built a potential multi-billion-dollar pipeline around this innovative drug delivery technology. In
We believe these strong results underscore the potential of | In January 2024, we initiated our third Phase 2 clinical trial for DURAVYU, the VERONA trial for diabetic macular edema (DME), and we look forward to reporting topline results in the DURAVYU brings a new mechanistic approach to the treatment of Turning to our early pipeline, in 2023 we announced a new | In addition, we
| ||
|
|
|
When it comes to matters of sight, innovation is our vision. |
|
| ||
|
|
| ||
| On behalf of the entire EyePoint team | Sincerely,
President & Chief Executive Officer
Goran Ando, M.D. Chairman of the Board
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. | ||
|
|
| ||
|
|
|
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this proxy deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes uncertainties regarding the timing and clinical development of our product candidates, including EYP-1901;EYP-1901 and EYP-2301; the potential for EYP-1901 as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration and non-proliferative diabetic retinopathy;retinopathy and diabetic macular edema ; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; extent to which our business, the medical communityapprovals including potential U.S. Food and the global economy will continue to be materiallyDrug Administration (FDA) regulatory approval of EYP-1901 and adversely impacted by the effects of the COVID-19 pandemic, or by other pandemics, epidemics or outbreaks;EYP-2301; the success of current and future license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effectsthe success of competition and other developments affecting sales of our commercialized products, YUTIQ® and DEXYCU®; the loss of pass-through reimbursement status for DEXYCUDurasert E™ as of January 1, 2023; market acceptance of oura drug delivery platform in FDA approved products; product liability; industry consolidation; compliance with environmental laws; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; the potential impact of the COVID-19 pandemic on EyePoint’s business, the medical community and the global economy, and the impact of general business and economic conditions; instability in macroeconomic factors including changes in inflation, interest rates and the labor market; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; manufacturing risks; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
NOTICE OF 20232024 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD JUNE 20, 20232024
Dear Stockholders:
NOTICE IS HEREBY GIVEN that the 20232024 Annual Meeting of Stockholders (Annual Meeting) of EyePoint Pharmaceuticals, Inc. (the Company) will be held on June 20, 20232024 at 9:00 a.m., Eastern Time. This year’s Annual Meeting will be a virtual meeting via live webcast on the Internet. You will not be able to attend the Annual Meeting in person. Instead, you will be able to attend the Annual Meeting by visiting www.meetnow.global/M2D47QY,MWRWKS9, for the following purposes:
The Company’s Board of Directors recommends that stockholders vote FOR ALL on Proposal No. 1 and FOR Proposal Nos. 2, 3, 4 & 4.5. During the ten days before the Annual Meeting, you may inspect a list of stockholders eligible to vote. If you would like to inspect the list, please call Jason D. Herpel, Vice President and Associate General Counsel, at (215) 817-4705 to arrange the inspection.
Stockholders of record at the close of business on April 21, 2023,23, 2024, the record date of the Annual Meeting, are entitled to notice of, and to vote at, the Annual Meeting and any adjournment or postponement of the meeting.
Important notice regarding the availability of proxy materials for the Annual Meeting to be held on June 20, 2023.2024. Our 20232024 Proxy Statement and Annual Report on Form 10-K for the year ended December 31, 20222023 are available at www.edocumentview.com/EYPT for street holders and www.envisionreports.com/EYPT for registered holders.
The accompanying proxy statement includes further details with respect to the proposals to be considered at the Annual Meeting. This notice of Annual Meeting and the accompanying proxy statement contain important information and should be read in their entirety. If you are in doubt as to how you should vote at the Annual Meeting, you should seek advice from your legal counsel, accountant, or other professional adviser prior to voting.
| By Order of the Board of Directors |
|
|
| Ron Honig |
| Chief Legal Officer and Company Secretary |
April 28, 202326, 2024
Watertown, Massachusetts
Table of Contents
In this proxy statement, the words “EyePoint,” “the Company,” “we,” “our,” “ours,” “us”, and similar terms refer to EyePoint Pharmaceuticals, Inc. and its consolidated subsidiaries, unless the context indicates otherwise.
The Notice of 20232024 Annual Meeting of Stockholders and Proxy Statement and our accompanying Annual Report on Form 10-K are being distributed and made available on or about May 5, 2023.6, 2024.
QUESTIONS AND ANSWERS
ABOUT
THE PROXY MATERIALS AND VOTING
Proxy Materials
Why am I receiving these proxy materials?
Our Board of Directors (Board) has made these proxy materials available to you on the Internet, or, upon your request, has delivered a printed or email copy of these proxy materials to you, in connection with its solicitation of proxies for use at our 20232024 Annual Meeting of Stockholders (Annual Meeting), which will take place on Tuesday,Thursday, June 20, 20232024 at 9:00 a.m., Eastern Time, via live webcast on the Internet by visiting www.meetnow.global/M2D47QY.MWRWKS9. We began sending the Notice of Internet Availability of Proxy Materials (Notice) on or about May 5, 2023.6, 2024. You received proxy materials because you owned shares of EyePoint common stock at the close of business on April 21, 2023 (the Record23, 2024 (Record Date), and that entitles you to vote at the Annual Meeting. These proxy materials describe the matters on which our Board of Directors would like you to vote and contain information that we are required to provide to you under the rules of the U.S. Securities and Exchange Commission (SEC) when we solicit your proxy.
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING TO BE HELD ON JUNE 20, 2023.2024. Our 20232024 Proxy Statement and Annual Report on Form 10-K for the year ended December 31, 20222023 are available at www.edocumentview.com/EYPT for street holders and www.envisionreports.com/EYPT for registered holders.
What is included in the proxy materials?
The proxy materials include:
What information is contained in this Proxy Statement and our Annual Report on Form 10-K?
The information in this Proxy Statement relates to the proposals to be voted on at the Annual Meeting, the voting process, the compensation of our directors and certain of our executive officers, corporate governance matters, and certain other required information. Our Annual Report contains information about our business, our audited financial statements and other important information that we are required to disclose under the rules of the SEC.
Why did I receive a notice in the mail regarding the Internet availability of proxy materials instead of a full set of proxy materials?
In accordance with SEC rules, we may furnish proxy materials, including this Proxy Statement and our Annual Report, to our stockholders by providing access to such documents on the Internet instead of mailing printed copies. Most stockholders will not receive printed copies of the proxy materials unless they request them. Instead, the Notice will instruct you as to how you may access and review all of the proxy materials on the Internet. The Notice also instructs you as to how you may submit your proxy or voting instructions on the Internet. If you would like to receive a paper or email copy of the proxy materials, you should follow the instructions in the Notice for requesting such materials.
1
How can I access the proxy materials over the Internet?
The Notice and, if you requested to receive a printed or email copy of these proxy materials, the proxy or voting instruction card that accompanied these materials, contains instructions on how to:
Our proxy materials are also available at www.edocumentview.com/EYPT for street holders and www.envisionreports.com/EYPT for registered holders.
Choosing to receive your future proxy materials by email will save us the cost of printing and mailing documents to you. If you choose to receive future proxy materials by email, you will receive an email next year with instructions containing a link to those materials and a link to the proxy voting site. Your election to receive proxy materials by email will remain in effect until you revoke it.
Voting Information
What items of business will be voted on at the Annual Meeting?
The items of business scheduled to be voted on at the Annual Meeting are:
Proposal No. 1: | To elect |
|
|
Proposal No. 2: | To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive |
|
|
Proposal No. 3: | To approve an amendment to the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 250,000 shares. |
Proposal No. 4: | To approve, on an advisory basis, the compensation paid to our named executive officers, as described in this proxy statement. |
|
|
Proposal No. | To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, |
See the “Proposals” section of this Proxy Statement for information on these proposals. We will also consider any other business that is properly brought before the Annual Meeting or any adjournments or postponements thereof. See “What happens if additional matters are presented at the Annual Meeting?” below.
How does the Board of Directors recommend that I vote?
Our Board recommends that you vote your shares as follows:
Board | ||
|
|
|
Proposal No. 1: | The election of | FOR ALL |
|
|
|
Proposal No. 2: |
| FOR |
2
|
|
|
Proposal No. 3: |
| FOR |
|
|
|
Proposal No. 4: |
| FOR |
Proposal No. 5 | To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, | FOR |
See the “Proposals” section of this Proxy Statement for information on these proposals and our Board’s recommendations.
What happens if additional matters are presented at the Annual Meeting?
Other than the fourfive items of business described in this Proxy Statement, we are not aware of any other business to be acted upon at the Annual Meeting. If you grant a proxy, the persons named as proxy holders, NancyJay S. Lurker,Duker, Chief Executive Officer and Ron I. Honig, Chief Legal Officer and Company Secretary, or either of them, will have the discretion to vote your shares on any additional matters properly presented for a vote at the Annual Meeting or any adjournments or postponements thereof. If, for any reason, any of the director nominees is not available as a candidate for director, the persons named as proxy holders will vote your proxy for such other candidate or candidates as may be nominated by our Board of Directors.
How many votes do I have?
There were 34,301,92652,084,148 shares of common stock issued and outstanding as of the close of business on the Record Date. Each share of our common stock that you ownowned as of the Record Date entitles you to one vote on each matter presented at the Annual Meeting. Cumulative voting for directors is not permitted.
What is the difference between holding shares as a “stockholder of record” as compared to as a “beneficial owner”?
Most of our stockholders hold their shares as a beneficial owner through a broker, bank, trust or other nominee rather than directly in their own name. As summarized below, there are some distinctions between shares held of record and those owned beneficially.
3
How can I vote my shares personally at the Annual Meeting?
You may vote your shares held in your name as the stockholder of record personally while participating in the Annual Meeting live via the Internet at www.meetnow.global/M2D47QYMWRWKS9 using your unique control number that was included in the Notice that you received in the mail, or, if you requested to receive a printed or email copy of these proxy materials, the proxy card that accompanied these materials.
If your shares are held beneficially in street name, you may still vote them at the Annual Meeting live via the Internet at www.meetnow.global/M2D47QYMWRWKS9 only if you obtain a legal proxy from the broker, bank, trustee, or other nominee that holds your shares giving you the right to vote the shares. Even if you plan to attend the Annual Meeting live via the Internet, we recommend that you also submit your proxy or voting instructions as described below so that your vote will be counted if you later decide not to attend the Annual Meeting personally.
How can I vote my shares without attending the Annual Meeting?
Whether you hold shares directly as the stockholder of record or beneficially in street name, you may direct how your shares are voted without attending the Annual Meeting.
Can I change my vote or revoke my proxy?
If you are the stockholder of record, you may change your vote at any time prior to the taking of the vote at the Annual Meeting by:
If you hold shares beneficially in street name, you may change your vote by:
•
Is my vote confidential?
Proxy instructions, ballots, and voting tabulations that identify individual stockholders are handled in a manner that protects your voting privacy. Your vote will not be disclosed either within our Company or to third parties, except: (1) as necessary to meet applicable legal requirements, (2) to allow for the tabulation of votes and certification of the vote, and (3) to facilitate a successful proxy solicitation.
4
What is a “broker non-vote”?
If you are a beneficial owner of shares held by a broker, bank, trust or other nominee and you do not provide your broker, bank, trustee or other nominee with voting instructions, your shares may constitute “broker non-votes.” Broker non-votes occur on a matter when the broker, bank, trustee or other nominee is not permitted under applicable stock exchange rules to vote on that matter without instructions from the beneficial owner and instructions are not given. These matters are referred to as “non-routine” matters.
Proposal Nos. 1, 2, 3 and 34 are considered “non-routine” matters, while Proposal No. 45 is considered a “routine” matter. Therefore, if you are a beneficial owner of shares held in street name and do not provide voting instructions, your shares will not be voted on Proposal Nos. 1, 2, 3 and 34 and a broker non-vote will occur on these matters. In tabulating the voting result for any particular proposal, shares that constitute broker non-votes are not considered votes cast with respect to that proposal. Thus, broker non-votes will not affect the outcome of any matter being voted on at the Annual Meeting, assuming that a quorum is obtained. Because Proposal No. 4
5 is a “routine” matter, a broker, bank, trustee, or other nominee will be permitted to exercise its discretion on this proposal, which means there will be no broker non-votes on this matter.
How many shares must be present or represented to conduct business at the Annual Meeting?
A “quorum” is necessary to conduct business at the Annual Meeting. A quorum is established if the holders of one-third of all shares issued and outstanding and entitled to vote at the Annual Meeting are present at the Annual Meeting, either in person via virtual communication or represented by proxy. Abstentions and broker non-votes will be counted as present for purposes of determining a quorum at the Annual Meeting. If a quorum is not present, the Annual Meeting will be adjourned until a quorum is obtained.
What are the voting requirements to approve the proposals discussed in this Proxy Statement?
5
Who will bear the cost of soliciting votes for the Annual Meeting?
We will pay the entire cost of preparing, assembling, printing, mailing and distributing these proxy materials, and soliciting votes. Our directors, officers, and employees may solicit proxies or votes in person, by telephone or by electronic communication. We will not pay our directors, officers, or employees any additional compensation for these services. We will ask brokers, banks, trustees, and other nominees to forward the proxy materials to their principals and to obtain authority to execute proxies and will reimburse them for certain costs in connection therewith.
Who will count the votes?
Votes will be counted by the inspector of election appointed for the Annual Meeting.
Where can I find the voting results of the Annual Meeting?
We will announce preliminary voting results at the Annual Meeting and disclose the final voting results in a Current Report on Form 8-K that we will file with the SEC within four business days of the Annual Meeting.
Attending the Annual Meeting
Why is the Annual Meeting being held virtually?
By hosting the Annual Meeting online, we are able to communicate more effectively with our stockholders, enable increased attendance and participation from locations around the world, and reduce costs and increase overall safety for both EyePoint and its stockholders. The virtual meeting has been designed to provide the same rights to participate as you would have at an in-person meeting. You will be able to vote online during the Annual Meeting, change a vote you may have submitted previously, or ask questions online that will be reviewed and answered by the speakers. You will only be able to participate in this manner if you log in with your holder control number.
Can I submit a question for the Meeting?
Stockholders who attend the Annual Meeting by webcast by visiting www.meetnow.global/M2D47QYMWRWKS9 will have an opportunity to submit questions in writing during a portion of the Annual Meeting. Instructions for submitting a question during the Annual Meeting will be provided on the Annual Meeting website. We will endeavor to answer as many submitted questions as time permits; however, we reserve the right to exclude questions regarding topics that are not pertinent to Annual Meeting matters or company business or are inappropriate. If we receive substantially similar questions, we will group such questions together and provide a single response to avoid repetition. Any questions that are appropriate and pertinent to the Annual Meeting but cannot be answered during the Annual Meeting due to time constraints will be answered and posted on the “Investors – Governance Documents” page of our Company’s website at www.eyepointpharma.com, as soon as practicable after the Annual Meeting.
What should I do if I need technical support during the Annual Meeting?
The Annual Meeting platform is fully supported across browsers and devices running the most updated version of applicable software and plugins. Attendees should ensure they have a strong internet connection, allow plenty of time to log in, and confirm they can hear streaming audio prior to the start of the Annual Meeting.
If you experience any technical difficulties accessing the Annual Meeting or during the Annual Meeting, please call the toll-free number that will be available on our virtual stockholder login site at www.meetnow.global/M2D47QYMWRWKS9 for assistance. We will have technicians ready to assist you with any technical difficulties you may have beginning 15 minutes prior to the start of the Annual Meeting, and the technicians will be available through the conclusion of the Annual Meeting. Additional information regarding matters addressing technical and logistical issues, including technical support during the Annual Meeting, will be available on the Annual Meeting website.
6
How can I attend the Annual Meeting?
The Annual Meeting will be a completely virtual meeting of stockholders, which will be conducted exclusively by webcast. You are entitled to participate in the Annual Meeting only if you were a stockholder of the Company as of the close of business on the Record Date, or if you hold a valid proxy for the Annual Meeting. No physical meeting will be held.
You will be able to attend the Annual Meeting online and submit your questions during the meeting by visiting www.meetnow.global/M2D47QY.MWRWKS9. You also will be able to vote your shares online by attending the Annual Meeting by webcast. To participate in the Annual Meeting, you will need to review the information included on your Notice, on your proxy card or on the instructions that accompanied your proxy materials.
If you hold your shares through an intermediary, such as a bank or broker, you must register in advance using the instructions below.
The online meeting will begin promptly at 9:00 a.m., Eastern Time. We encourage you to access the meeting at least 15 minutes prior to the start time and to leave ample time for the check in. Please follow the registration instructions as outlined in this proxy statement.
How do I register to attend the Annual Meeting virtually on the Internet?
•
You will receive a confirmation of your registration by email after we receive your registration materials.
Requests for registration should be directed to us at the following:
By email:
Forward the email from your broker, or attach an image of your legal proxy, to legalproxy@computershare.com.
By mail:
Computershare
EyePoint Pharmaceuticals, Inc. Legal Proxy
P.O. Box 43001
Providence, RI 02940-3001
7
DIRECTORS AND EXECUTIVE OFFICERS
Directors and Director Nominees
Our Board consists of eight (8)ten (10) directors. The term of each director expires each year at our Annual Meeting of Stockholders. Each director also continues to serve as a director until his or her successor is duly elected and qualified, or until he or she sooner dies, resigns, or is removed. Ye Liu will not stand for re-election at our annual Meeting but will continue to serve as a director until the expiration of his term at the Annual Meeting. The size of the Board will remain at eight (8)be reduced to nine (9) members as of the Annual Meeting.
The following table sets forth the name, age, director service period and position of each of our current directors and director nominees as of April 21, 2023:xx, 2024, other than Mr. Liu who will not stand for re-election at our Annual Meeting:
Name |
| Age |
| Position |
| Director Since |
| Age |
| Position |
| Director Since |
Göran Ando, M.D. |
| 74 |
| Chair of the Board of Directors |
| 2018 |
| 75 |
| Chair of the Board of Directors |
| 2018 |
Jay S. Duker, M.D. |
| 65 |
| President, Chief Executive Officer and Director |
| 2016-2020, 2023 | ||||||
Nancy Lurker |
| 65 |
| Chief Executive Officer and Director |
| 2016 |
| 66 |
| Executive Vice Chair of the Board of Directors |
| 2016 |
John B. Landis, Ph.D. |
| 70 |
| Director |
| 2018 |
| 71 |
| Director |
| 2018 |
David Guyer, M.D. |
| 63 |
| Director |
| 2019 |
| 64 |
| Director |
| 2019 |
Wendy DiCicco |
| 55 |
| Director |
| 2019 |
| 56 |
| Director |
| 2019 |
Ye Liu |
| 52 |
| Director |
| 2020 | ||||||
Anthony P. Adamis, M.D. |
| 64 |
| Director |
| 2022 |
| 65 |
| Director |
| 2022 |
Karen Zaderej |
| 61 |
| Director |
| 2022 |
| 62 |
| Director |
| 2022 |
Stuart Duty |
| 59 |
| Director |
| 2023 | ||||||
|
|
|
|
|
Board Diversity Matrix
The following Board Diversity Matrix presents our Board diversity statistics in accordance with Nasdaq Rule 5606, as self-disclosed by our directors and director nominee:
Board Diversity Matrix (As of April 21, 2023) | ||||||||
Board Diversity Matrix (As of April 26, 2024) | Board Diversity Matrix (As of April 26, 2024) | |||||||
Total Number of Directors | 8 | 10 | ||||||
| Female | Male | Non-Binary | Did Not Disclose Gender | Female | Male | Non-Binary | Did Not Disclose Gender |
Part I: Gender Identity |
|
| ||||||
Directors | 3 | 5 | 0 | 3 | 7 | 0 | ||
Part II: Demographic Background | Part II: Demographic Background | Part II: Demographic Background | ||||||
African American or Black | 0 | 0 | ||||||
Alaskan Native or Native American | 0 | 0 | ||||||
Asian | 0 | 1 | 0 | 0 | 1 | 0 | ||
Hispanic or Latinx | 0 | 0 | ||||||
Native Hawaiian or Pacific Islander | 0 | 0 | ||||||
White | 3 | 4 | 0 | 3 | 6 | 0 | ||
Two or More Races or Ethnicities | 0 | 0 | ||||||
LGBTQ+ | 0 | 0 | ||||||
Did Not Disclose Demographic Background | 0 | 0 |
The diversity matrix of our Board of Directors for the year ended December 31, 2022 is available in our proxy statement for the 2023 annual meeting of our stockholders, filed with the SEC on April 14, 2023.
Set forth below for each director standing for election at the Annual Meeting is a list of Board Committee memberships and a description of his or her business experience, qualifications, education and skills that led our Board to conclude that such individual should serve as a member of our Board:
Göran Ando, M.D.
Chair of the Board and the Governance and Nominating Committee, member of the Compensation Committee and the Science Committee
8
Dr. Ando has had a distinguished career in the global pharmaceutical industry that has spanned nearly four decades. He began his career at Pfizer, Inc., where he held several senior clinical positions both in the U.S. and in Europe. Dr. Ando also served as President of the Astra Research Centre. He held various senior appointments at GlaxoSmithKline plc, including Research and Development Director for Glaxo Group Research. Dr. Ando then joined Pharmacia AB in 1995 as Executive Vice President and Deputy Chief Executive Officer to lead Research and Development with additional responsibilities for manufacturing, information technology, business development, and M&A. During his nine-year tenure as Head of Research and Development at Pharmacia/Pharmacia &
Upjohn, 17 new drugs were approved by the FDA prior to Pharmacia’s acquisition by Pfizer for $60 billion. Dr. Ando retired in 2018 as Chairman of Novo Nordisk A/S and previously served as the Chief Executive Officer of Cell Tech Group PLC from 2003 to 2005. He currently serves as Chairman of the Board for Nouscom A/G (a private company in Switzerland). Dr Ando has served as the Chairman of and Nanexa (a public Company in Sweden) since 2020.AB (Sweden). Previously, he has served as Chairman of the Board for several European-based biopharmaceutical companies, and, until April 2020, he served as a board member of Molecular Partners (a public company listed on the Swiss exchange) and. He served as a Senior Advisor at EW Healthcare Partners from 2007 to July 2021. From December 2020 to December 2022, Dr. Ando served as a Director of the Board for Selecta Bio (NASDAQ: SELB). Dr. Ando received his Bachelor of Arts degree from Uppsala University in Sweden and Doctor of Medicine degree from Linköping University in Sweden.
We believe Dr. Ando is qualified to serve as Chair of our Board because his strong record of leadership as an executive officer and director in the life sciences industry affords him a deep understanding of the industry and corporate setting in which we operate and allows him to impart his substantial expertise in the fields of manufacturing, information technology, business development and commercialization to the Board and the Company.
Jay S. Duker, M.D
President, Chief Executive Officer and Director
Dr. Duker has beenEyePoint’s President, Chief Executive Officer and a Director since July 2023. Prior to these roles, Dr. Duker served EyePoint as President and Chief Operating Officer and as Chief Strategic Scientific Officer. He was an independent Director on EyePoint’s Board of Directors from 2016-2020 before his re-appointment to the Board of Directors in July 2023.
Between 2001 and 2021, Dr. Duker was the Director of the New England Eye Center (NEEC) and Professor and Chair of the Department of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine in Boston, Massachusetts. He has published over 345 journal articles, concentrating on retinal imaging, retinal vascular diseases, and drug delivery to the posterior segment. Dr. Duker remains in clinical practice, seeing patients with medical retinal disorders and intraocular tumors. Dr. Duker is the founder of three successful start-up companies; SurgiSite Boston, the fifth busiest independent ophthalmology-only out-patient surgery center in the United States, the Boston Image Reading Center (BIRC), and Hemera Biosciences, the developer of HMR59, an AAV-based gene therapy for dry age-related macular degeneration that is currently in a phase 2 clinical trial after being acquired by Janssen in 2020. Dr. Duker was on the Board of Sesen Bio and served as its Chair until March 2023. Dr. Duker received an A.B. from Harvard University and an M.D. from the Jefferson Medical College of Thomas Jefferson University.
Dr. Duker has devoted more than 30 years to the field of ophthalmology focused on improving eyesight and preventing blindness, holding roles in clinical research, business, and academic settings. We believe Dr. Duker is qualified to serve on our Board because of his role as President and Chief Executive Officer, as well his prior service on the Board of the Company and other life science companies. Dr. Duker's extensive experience in ophthalmology, both as a renowned practitioner, scholarly leader and successful executive, provides him with valuable expertise to guide our Board.
Nancy Lurker
Chief
Executive OfficerVice Chair of the Board of Directors
Ms. Lurker has been ourserved as Executive Vice Chair of EyePoint's Board of Directors since July 2023. Prior to this role, Ms. Lurker served as President and Chief Executive Officer since September 2016 and served as our Presidentof EyePoint from September 2016 to JanuaryJuly 2023. From 2008Prior to 2015,EyePoint, Ms. Lurker served as President and Chief Executive Officer and a director of PDI, Inc. (now Interpace Diagnostics Group, Inc.) (OTC: IDXG), a Nasdaq-listedpublicly-traded healthcare commercialization company, now named Interpace Diagnostics Group, Inc. From 2006 to 2007, Ms. Lurker wasand as Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG. From 2003Prior to 2006, she served as President and Chief Executive Officer of ImpactRx, Inc., a privately held healthcare information company. From 1998 to 2003,that, Ms. Lurker served as Group Vice President, Global Primary Care Products and Vice President, General Therapeutics forheld various senior positions at other leading pharmaceutical companies including Pharmacia Corporation (Pharmacia), now(now a part of Pfizer, Inc. She also served as a member of Pharmacia’s U.S. executive management committee. Previously, Ms. Lurker spent 14 years at), ImpactRx and Bristol-Myers Squibb Company, rising from a sales representative to Senior Director, Worldwide Cardiovascular Franchise Management. Since April 2018, Company.
Ms. Lurker currently serves as a member ofon the board of directors of Aquestive TherapeuticsAlkermes plc (Nasdaq: AQST)ALKS), Altasciences, LLC, a Nasdaq-listed company. Since April 2021, Ms. Lurker has served asprivate contract research organization and National Sanitation Foundation, a member of the board of directors of Altasciences (a private company in Canada). Ms. Lurkernot-for-profit organization dedicated to improving human health through
9
quality standards. She previously served as a member ofon the boardboards of directors of the Cancer Treatment Centers of America. Ms. Lurker also previously served as Chair of the board of directors ofAmerica, and current and formerly publicly-traded companies Aquestive Therapeutics, Inc. (NASDAQ: AQST), X4 Pharmaceuticals, Inc. (Nasdaq:(NASDAQ: XFOR) from 2016 to 2018, and as a member of the boards of directors of publicly held, Auxilium Pharmaceuticals, Inc. from 2011 to 2015,, Mallinckrodt Pharmaceuticals, plc, from 2013 to 2016, Elan Pharmaceuticals from 2005-2006, Conjuchem Biotechnologies from 2004-2006 in addition to serving as a director of PDI, Inc. from 2008 to 2015., Elan Corporation, plc, and ConjuChem Biotechnologies. Ms. Lurker receivedholds a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville.
We believe Ms. Lurker is qualified to serve on our Board because of her role as Chief Executive Officer, as well as her broad ranging experience in the pharmaceutical industry and her track record of maximizing the potential of new therapies with over tentherapies. Ms. Lurker's years of clinical drug development at BMS, Pharmacia and Novartis, in her capacity as a senior executive, and successfully implementing innovative U.S. and global drug launches, which provide her with valuable expertise and perspective on our corporate strategy, management, operations, and governance.
John B. Landis, Ph.D.
Chair of the Science Committee
Dr. Landis has served as a Director since 2018, and a GMP Consultant to EyePoint, leading the EyePoint GMP process, since December 2023. Dr. Landis served as a director for Bioanalytical Systems, Inc. (NASDAQ: BASI), from 2009 to 2017, serving as the Chairman of its board of directors from 2011 until his departure in 2017. Dr. Landis previously served as Senior Vice President, Pharmaceutical Sciences of Schering-Plough Corporation, a pharmaceutical company, from September 2003 until his retirement in October 2008. In that role, Dr. Landis led the global pharmaceutical sciences function of pharmacy, analytical chemistry, process chemistry, biotechnology, quality assurance, clinical supplies, and devices. Prior to that, Dr. Landis served as Senior Vice President, Preclinical Development at Pharmacia Corporation from 1997 until 2003 and led the global preclinical functions of toxicology, drug metabolism and pharmacokinetics, pharmaceutical sciences, analytical chemistry, and laboratory animal care. Dr. Landis also served as Vice President, Central Nervous System Psychiatry, Critical Care and Inflammation Development for Pharmacia & Upjohn from 1995 through 1997. Prior to that, Dr. Landis was employed by The Upjohn Company, where he held positions of increasing responsibility in the areas of analytical research, quality assurance, and quality control. He is a current member of Purdue University’s Drug Discovery Board. Over his career, Dr. Landis served on several other boards of directors, academic advisory panels, and professional boards. Dr. Landis earned Ph.D. and M.S. degrees in Analytical Chemistry from Purdue University and a B.S. degree in Chemistry from Kent State University.
We believe Dr. Landis is qualified to serve on the Board because his substantial and varied experience working within medical communities ranging from academia to the pharmaceutical industry position him to provide a practical and balanced perspective to the Board. Dr. Landis also brings to the Board executive experience in clinical research and his service on other public company boards affords him a deep understanding of the role of the Board and its oversight of corporate governance and business strategy.
David Guyer, M.D.
Chair of the Compensation Committee and member of the Audit Committee, Governance and Nominating Committee and the Science Committee
David R. Guyer, M.D. is a Chief Executive Officer of EyeBio, a privately held ophthalmology biotechnology company and a Venture Partner at SV Health Investors. Dr. Guyer was the co-founder and served as Executive Chairman of Iveric Bio (formerly Ophthotech) (Nasdaq: ISEE) until 2021. Dr. Guyer served as a director for Applied Genetic Technologies Corporation (Nasdaq: AGTC) from June 2014 to December 2017. Dr. Guyer served as Chairman of Iveric Bio’s board of directors since its inception in January 2007 to January 2017 and as the Chief Executive Officer from April 2013 to January 2017. Under his leadership, Ophthotech entered into one of the largest ex-US partnering transactions ever in the biotechnology industry at that time with Novartis.
Dr. Guyer has significant medical, drug development, and commercial experience in ophthalmology, and in his career has served on approximately 20 boards of both public and private companies. He co-founded Eyetech Pharmaceuticals Inc. and served as its Chief Executive Officer and as a member of its board of directors from 2000 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005.
Prior to co-founding Eyetech Pharmaceuticals, Dr. Guyer was a professor and served as Chairman of the Department of Ophthalmology at New York University School of Medicine. Dr. Guyer received a BS from Yale College and an MD from Johns Hopkins Medical School. Dr. Guyer completed his ophthalmology residency at Wilmer Ophthalmological Institute, Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.
We believe Dr. Guyer is qualified to serve on the Board because of his extensive executive leadership experience, his extensive experience in ophthalmology, his extensive experience in the life sciences industry as an entrepreneur and venture capital investor, and his service on the board of directors of other life sciences companies.
10
Wendy DiCicco
Chair of the Audit Committee and member of the Compensation Committee and the Governance and Nominating Committee
Ms. DiCicco serves as an independent financial and board advisor to companies in the life sciences industry, often serving in the role of interim Chief Financial Officer. Since July 2023 she has served as the interim Chief Financial Officer for Akari Therapeutics (NASDAQ: AKTX). From 2019 to DecemberMarch 2022, she served as interim Chief Financial Officer (interim through March 2022) for Renovacor, a preclinical stage biopharmaceutical company (NYSE: RCOR). Previously, she was Chief Operating and Financial Officer of Centinel Spine from 2017 to 2018, a privately-held company. Ms. DiCicco served as a member ofcurrently serves on the board of directors of SWK Holdings Corp (Nasdaq: SWKH) from February 2022 through March 2023. Ms. DiCicco currently serves on the boards of directors of Imvax, Inc. and ExpressCells,Inc a privately-held biotechnology companies,company, and previously served on the boards of directors of SWK Holdings Corp (NASDAQ:SWKH), Sincerus Pharmaceuticals, ExpressCells, II-VI, Inc. (Nasdaq:(NASDAQ: II-VI) from 2006 until 2017, Sincerus Pharmaceuticals from 2021 through 2022,, Carmell Therapeutics, from 2018 until 2021, Syncardia Systems, and CannaPharma Rx (OTC: CPMD). She previously served as President and Chief Operating Officer of Camber Spine Technologies and has held Chief Financial Officer roles at Nuron Biotech, Quench USA, Globus Medical, and Kensey Nash Corporation. Her career started in public accounting at Deloitte & Touche in 1990. Ms. DiCicco received a B.S. in accounting from Philadelphia College of Textiles and Science and is a licensed CPA. She is also an appointed Board Leadership Fellow and Corporate Governance Fellow of the National Association of Corporate Directors (NACD).
We believe Ms. DiCicco is qualified to serve on our Board because of her highly successful career as a C-suite executive leading financial and operational organizations at numerous global, commercial-stage healthcare companies and her extensive strategic and financial expertise to expand commercial launch efforts.
Ye Liu
Mr. Liu has over 20 years of experience in the pharmaceutical industry. Since November 2018, he has served as executive director and Chief Executive Officer of Ocumension Therapeutics (a company listed on Hong Kong Stock Exchange, stock code: 1477) (Ocumension), a China-based ophthalmic pharmaceutical company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies.
Prior to joining Ocumension Therapeutics, Mr. Liu served as the chairman and general manager at Santen Pharmaceutical (China) Co., Ltd. from October 2014 to July 2018. From February 2009 to September 2014, Mr. Liu served as the head of the pharmaceutical affair division and later became the general manager of Eisai (China) Inc., responsible for the management of pharmaceutical affairs and development, and the overall corporate operation, respectively. From October 2006 to February 2009, Mr. Liu held positions including the national sales, senior business development manager, and the head of sales at Sandoz China Pharmaceutical Co., Ltd., responsible for marketing, sales and business development. Mr. Liu received a B.S. from Shanghai Medical University and an M.Sc. from Dalhousie University.
We believe Mr. Liu is qualified to serve on the Board because of his extensive executive leadership experience and his extensive experience in the life sciences industry in both sales and pharmaceutical development.
Anthony P. Adamis, M.D.
Member of the Science Committee
Dr. Adamis has served as the co-founder and director for EyeBio, a privately held ophthalmology biotechnology company since August 2021, where he also has served as Chief Scientific Officer since 2022. Dr Adamis serves as director of Theia, a privately held ophthalmology biotechnology company since November 2021, as a director of Spiral, a privately held non-ophthalmic biotechnology company since October 2021 and as a director for RD Funds, the venture arm of the Foundation Fighting Blindness since October 2021,2021.
Previously, Dr Adamis served as a director of Theiafor Gyroscope Therapeutics Holdings plc, a preclinical stageclinical-stage gene therapy company focused on treatments for retinal diseases since Novemberof the eye from 2021 a director of Spiral Therapeutics, a clinical development stage company focused on hearing loss since October 2021, and One Bio, a clinical stage company focused on pulmonary disease since Apriluntil its acquisition by Novartis in 2022. He has also served as Senior Vice President of Development Innovation at Genetech,Genentech, now a wholly owned member of the Roche Group since 2009.from 2018 to 2021. He is best known for his co-discovery of the central role of vascular endothelial growth factor (VEGF) in two leading causes of blindness: neovascular age-related macular degeneration (nAMD) and diabetic retinopathy. Conducted at Harvard in the 1990s, this research led to Dr. Adamis’ shared receipt of the Antonio Champalimaud Award, the highest honor in vision science, and to his election to the National Academy of Medicine.
Over the course of his career, Dr. Adamis has helped develop 20 medicines across 30 indications, resulting in seven FDA Breakthrough Designations and 2526 FDA approvals. Dr. Adamis received his M.D. from the University of Chicago, his ophthalmology training at the University of Michigan, and his fellowship training at Harvard University. He completed his research training in vascular biology with Judah Folkman, M.D., at Boston Children’s Hospital.
We believe Dr. Adamis is qualified to serve on the Board because of his extensive executive leadership experience, his extensive experience in ophthalmology, his extensive experience in the life sciences industry, and his service on the board of directors of other life sciences companies.
Karen Zaderej
Member of the Audit Committee
Ms. Zaderej has more than 35 years of biopharmaceutical and medical device experience. She currently serves as President, Chief Executive Officer, and Chair of the Board at AxoGen.Axogen (NASDAQ: AXGN). Earlier in her career, she held positions of increasing responsibility at AxoGen,Axogen, including Chief Operating Officer and Vice President of Marketing and Sales. Prior to joining AxoGenAxogen in 2006, Ms. Zaderej worked for Zaderej Medical Consulting, a consulting firm she founded to assist medical device companies to build and execute successful commercialization plans. Previously, she worked at Ethicon, Inc., a Johnson & Johnson company, where she
11
held senior positions in marketing, business development, research & development, and manufacturing. Ms. Zaderej is a member of the Executive Committee and the Board of Trustees of the University of Tampa. She holds an M.B.A. from the Kellogg Graduate School of Business and a B.S. in Chemical Engineering from Purdue University.
We believe Ms. Zaderej is qualified to serve on the Board because of her extensive executive leadership experience, extensive experience in commercial development and her extensive experience at other life sciences companies.
Stuart Duty
Member of the Audit Committee
Stuart Dutyis an experienced financial executive with over 30 years of experience in finance and investment banking. Mr. Duty has served as a director of Achieve Life Sciences, Inc. since March 2023.
Previously, Mr. Duty was a Senior Managing Director of Guggenheim Securities, LLC, a global investment, and advisory financial services firm, from June 2012 to March 2023. He also served as Managing Director, Co-Head, Healthcare Investment Banking at Piper Jaffray Companies, a global investment firm, from 2007 to 2012, as the Chief Operating Officer of Oracle Partners, L.P., a private healthcare focused investment fund, from 2002 to 2007, as Managing Director, Co-Head, Healthcare Investment Banking at Piper Jaffray, Inc., an global investment bank, from 1992 to 2002, as Managing Director, Healthcare Investment Banking at Montgomery Securities, an investment bank, from 1993 to 1999 and as the Director of Business Development at Curative Technologies, Inc., a biotherapeutics company, from 1992 to 1993. Mr. Duty holds a B.A. in Biochemistry from Occidental College and an M.B.A. from Harvard Business School.
We believe Mr. Duty is qualified to serve on the Board because of his extensive finance and investment banking experience, having guided numerous biotechnology and specialty pharmaceuticals companies through transactions and capital raise stages of growth.
Executive Officers
Each of our executive officers holds office until the first meeting of our Board following the next annual meeting of stockholders and until such officer’s respective successor is chosen and qualified, unless a shorter period shall have been specified by the terms of such officer’s election or appointment. The following table sets forth information about our executive officers as of April 21, 2023:23, 2024:
Name |
| Age |
| Position |
|
| 65 |
| President, Chief Executive Officer |
|
|
| ||
George Elston |
|
| Executive Vice President and Chief Financial Officer | |
Ramiro Ribeiro, M.D. | 41 |
| Chief | |
|
|
| ||
|
|
| ||
|
|
|
Nancy LurkerJay Duker, M.D.
Please refer to the section entitled “Directors and Executive Officers – Directors and Director Nominees” above for Ms. Lurker’sMr. Duker’s biographical information.
Jay Duker, M.D.
Dr. Duker has served as our President and Chief Operating Officer since January of 2023 and Chief Operating Officer since November 2021. Dr. Duker served as our Chief Strategic Scientific Officer on a part-time basis in 2020, after having served as an independent member of our Board of Directors since 2016. Dr. Duker was the Director of the New England Eye Center from 2001 to 2021 and Chair of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine over the same period. Dr. Duker has co-founded three start-ups, including Hemera Biosciences, a gene therapy company that developed an anti-complement treatment for dry macular degeneration, which was acquired by Janssen in 2020. In addition, Dr. Duker was the Chair of the Board of Sesen Bio, a publicly traded clinical stage biopharmaceutical company until March 2023. He is currently on the Board of Hubble Bio. He has published more than 300 journal articles related to ophthalmology and is co-author of Yanoff and Duker’s Ophthalmology, a best-selling ophthalmic textbook. Dr. Duker received an A.B. from Harvard University and an M.D. from the Jefferson Medical College of Thomas Jefferson University.
George Elston
Mr. Elston has served as our Executive Vice President and Chief Financial Officer since October 2023. From November 2019.2019 to October 2023, Mr. Elston served as Chief Financial Officer. Mr. Elston brings more than 25 years of diverse financial and senior leadership experience in the biopharmaceutical sector with both global publicly-traded and privately-held organizations. Mr. Elston most recently served as Chief Financial Officer and Head of Corporate Development at Enzyvant Therapeutics from December 2018 to September 2019 where he helped build the pre-commercial rare disease firm leading to its recent 2019 acquisition. Before that, he was President and Chief Executive Officer at 2X Oncology, Inc. from May 2017 to October 2018, where he advanced the company from a spin-out into a multiprogram, clinical-stage organization. He was also SVP and CFO of Juniper Pharmaceuticals, Inc. from October 2014 to December 2016 and prior to that, held senior executive roles at KBI Biopharma, Inc., Optherion, Inc., Elusys Therapeutics, Inc. and CR Bard. Mr. Elston began his career in public accounting at Pricewaterhouse (now PricewaterhouseCoopers LLP). He earned his B.B.A. in accounting from Pace University and is a Certified Public Accountant. He currently serves as a Trustee and Audit Committee Chairman of the DWS – DBX ETF Trust.
Dario Paggiarino,12
Ramiro Ribeiro, M.D., PhD
Dr. PaggiarinoRibeiro has served as our Senior Vice President and Chief Medical Officer since April 2019,March 2024, and was previously Vice President Chief Medical Officer since August 2016. Prior to that, Dr. Paggiarino served since April 2013 as Senior Vice President and Chief Development Officer of Lpath, Inc., a biotechnology company focused on the discovery and development of lipidomic-based therapeutic antibodies that target bioactive signaling lipids to treat a wide range of human diseases. Dr. Paggiarino served as Vice President and Therapeutic Unit Head for retina diseases at Alcon, a division of Novartis from 2011 to 2013. He served as Executive Director of Clinical Development and Medical Affairs at Pfizer Global R&D, a division of Pfizer, Inc., from 2001 to 2011. Earlier in his career, he held research and development positions of increasing responsibility at AngeliniApellis Pharmaceuticals Inc., an affiliate of Angelini S.p.A, a privately-owned company, ultimately serving as president, and later joined Pharmacia Global R&D, a division of Pharmacia Corporation, where he (NASDAQ: APLS) from 2018 to 2024. In his previous role, Dr. Ribeiro was responsible for building the pipeline strategy for Apellis’s ophthalmology franchise. He successfully led the cross-functional development team responsible for the global Phase 3 clinical program director of ophthalmology. Dr. Paggiarino obtained a Medical Doctor (M.D.) degree (Cum Laude)in Geographic Atrophy (GA) from the University of Rome School of Medicine, Italy,protocol development through New Drug Application (NDA) submission and the Italy DepartmentU.S. FDA approval of Health Board Certification in General Medicine and Surgery.
Scott Jones
Mr. Jones has served as our Chief Commercial Officer since June 2019.SYFOVRE. Prior to that, from 2013 to June 2019, Mr. Jones servedjoining Apellis in various roles at Notal Vision, an ophthalmological diagnostic services company, most recently as Chief Commercial Officer, Vice President of Business Development, and earlier as President. Before joining Notal Vision, from 2009 to 2013, Mr. Jones served as President of QLT Ophthalmics. Prior to that, from 2006 to 2009, Mr. Jones served as Executive Director, Health Policy at Novartis Pharmaceuticals. Mr. Jones also served as Executive2018, Dr. Ribeiro was the Senior Medical Director and Head of Market AccessDigital Health at Acucela Inc., where he was responsible for multiple programs in retina. Previously, he held leadership roles at Ophthotech (Iveric Bio), Alcon (NYSE: ALC), Replenish, Inc., and Government Affairs at Novartis Ophthalmics1Co Inc. Earlier, Dr. Ribeiro was a practicing retinal specialist. He holds a M.D. from 2004 to 2006, as well as other roles of varying responsibility at Novartis and at Ciba Geigy from 1989 to 2004. Mr. Jones received an M.A. in political sciencePontifical Catholic University and a CertificatePh.D. in Public AdministrationStem Cell Therapy for Retinal Degenerative Diseases from the Federal University of Florida, as well asSão Paulo. He was also a Bachelorresearch fellow at University of Science in Chemistry.Southern California.
Michael Pine
Mr. Pine has served as our Chief Corporate Development and Strategy Officer since January 2022. Prior to that, Mr. Pine served as Senior Vice President of Business Development and Strategy at Medexus Pharmaceuticals since September 2020. Mr. Pine held roles of increasing responsibility at Lupin Pharmaceuticals from 2019 to 2020, Aralez Pharmaceuticals from 2015 to 2019, and Novartis Pharmaceuticals from 2007 to 2015, where he built a diverse skill set in business development, commercial, operational and strategy roles. Earlier in his career, Mr. Pine was in business development roles at Kos Pharmaceuticals, Organon Biosciences, and Pfizer, as well as an Investment Banking Analyst at JP Morgan Chase. Mr. Pine holds a B.S. in Consumer Economics from Cornell University and an M.B.A from Columbia Business School.
Family Relationships
There are no family relationships among any of our directors, director nominees or executive officers.
Arrangements between Officers, Directors and Director Nominees
Per the terms of that certain Securities Purchase Agreement, dated March 28, 2018, by and among us, EWHP and EWHP-A (First Tranche Securities Purchase Agreement), EW Healthcare Partners, L.P. (EWHP), and EW Healthcare Partners-A, L.P. (EWHP-A) have the right, subject to certain customary limitations and restrictions, to nominate one individual to our Board for so long as they beneficially own shares of our common stock. Per the terms of that certain Second Tranche Securities Purchase Agreement, dated March 28, 2018, by and among us, EWHP, EWHP-A and the other accredited investors signatory thereto, (Second Tranche Securities Purchase Agreement), EWHP and EWHP-A have the right, subject to certain customary limitations and restrictions, to nominate one additional individual to our Board for so long as they beneficially own shares of our common stock. Dr. Ando was initially appointed to the Board as the designee of EWHPEW Healthcare Partners, L.P. and EWHP-A,EW Healthcare Partners-A, L.P. pursuant to the terms of a securities purchase agreement between us and the Second Tranche Securities Purchase Agreement. Dr. Ando served as Senior Advisorinvestors. The investors no longer have board nomination rights pursuant to EWHP, which is an affiliate of both EWHP and EWHP-A until July 2021.such agreement.
On December 31, 2020, we entered into a Share Purchase Agreement (Share Purchase Agreement) withDr. Liu was initially appointed to the Board as the designee of Ocumension pursuant to which we offeredthe terms of a share purchase agreement between us and soldOcumension. Ocumension no longer has board nomination rights pursuant to Ocumension 3,010,722 shares of our common stock at a purchase price of $5.2163 per share. On December 31, 2020, we entered into a Voting and Investor Rights Agreement (Voting Agreement), with Ocumension, EWHP and EWHP-A. Pursuant to the Voting Agreement, for so long as Ocumension owns a number of shares of our common stock equal to at least 75% of the shares of our common stock it acquired on December 31, 2020, and subject to compliance with applicable law and our guidelines with respect to the nomination of directors, Ocumension is entitled to designate for nomination one person (Investor Designee) to serve as a member of our Board, the Science Committee and certain other ad-hoc committees of the Board. Notwithstanding the foregoing, in accordance with Nasdaq Listing Rule 5640, Ocumension will not be entitled to designate for nomination any person to serve as a member of our Board if, at any time, Ocumension owns a number of shares of our common stock representing less than 5% of the shares of our common stock outstanding. Pursuant to the Voting Agreement, for so long as EWHP and EWHP-A beneficially own at least 10% of the outstanding shares of our common stock, EWHP and EWHP-A agreed to vote in favor of the Investor Designee at each election of the Board. The initial Investor Designee is Ye Liu.such agreement.
Other than as disclosed above, there is no arrangement or understanding between any of our executive officers, directors or director nominees and any other person, pursuant to which such person was selected to serve as an executive officer or director, as applicable.
CORPORATE GOVERNANCE AND BOARD MATTERS
Director Independence
The Board has unanimously determined that Dr. Ando, Dr. Landis, Dr. Guyer, Ms. DiCicco, Dr. Adamis, and Ms. Zaderej, and Mr. Duty are independent under applicable standards of the SEC and Nasdaq. Dr. Duker does not qualify as independent due to the fact that Dr. Duker serves as President and Chief Executive Officer of the Company. Ms. Lurker does not qualify as independent due to the fact that Ms. Lurkershe serves as the Executive Vice Chair of the Board and previously served as President and Chief Executive Officer. Mr. LiuOfficer of the Company. Our Board determined that Dr. Landis does not qualify as independent due to the fact that he currently serves as Executive Director and Chief Executive Officer of Ocumension. In January 2020, we signed an exclusive license agreement (License Agreement) with Ocumension for the development and commercialization of DEXYCU for the treatment of post-operative inflammation following ocular surgery in Mainland China, Hong Kong, Macau and Taiwan. Under the terms of the License Agreement,a consultant to EyePoint leading the Company received an upfront payment of $2 million from Ocumension. On August 20, 2020, the Company entered a Memorandum of Understanding (MOU) with Ocumension, pursuant to which the Company received a one-time $9.5 million payment from Ocumension as consideration for the expansion of the territories included in the License Agreement. Mr. Liu does not qualify as independent due to the fact that the payments under the License Agreement and the MOU exceeded permissible amounts to retain such independence as set forth in Nasdaq Rule 5605(a)(2)(D).GMP process.
Each of the Audit Committee, the Compensation Committee and the Governance and Nominating Committee is comprised entirely of independent directors. TheOther than Dr. Landis, the Science Committee is also comprised entirely of independent directors.
Board Leadership Structure, Processes, and Role in Risk Oversight
Board Leadership Structure
The Board has chosen to separate the roles of Board Chair and Chief Executive Officer and believes that such a separation of roles is in our best interests and the best interests of our stockholders. Dr. Ando’sAndo's extensive experience in the life sciences industry in both senior management and board of director positions coupled with his perspective as an independent director provide effective leadership for our Board and support for our executive team. The leadership structure also includes an Executive Vice Chair to the Board of Directors. Ms. Lurker's broad ranging experience in leading the Company and her track record of maximizing the potential of new therapies with over ten years of clinical drug development experience as a senior executive, and successfully implementing innovative U.S. and global drug launches, provide her with valuable expertise to provide leadership for our Board and support of the executive team.
13
Board’s Role in Risk Oversight
It is management’s responsibility to manage risk and bring to the Board’s attention risks that are material to the Company. The Board has oversight responsibility for the systems established to report and monitor the most significant risks applicable to us. The Board administers its risk oversight role directly and through its committee structure. The Board reviews strategic and financial risks and exposures associated with our long-term strategy, development, and commercialization of products and product candidates and other matters that may present material risk to our operations, strategy, and prospects. The Audit Committee reviews risks associated with financial and accounting matters, including financial reporting, accounting, disclosure and internal control over financial reporting, as well as overall risk assessment and management, including risks associated with information technology (cybersecurity) and compliance (including healthcare and related regulatory matters). The Compensation Committee reviews risks related to executive compensation and the design of compensation programs, plans and arrangements, as well as risks and overall approach related to human capital matters, including diversity and inclusion, employee engagement, and culture. The Governance and Nominating Committee manages risks associated with corporate governance, as well as Board composition and procedures. The Science Committee supports the Board’s oversight of risks related to our research and development (R&D) organization.
Executive Sessions
Executive sessions of our independent directors are held at each regularly scheduled meeting of our Board and at other times they deem necessary. Our Board’s policy is to hold executive sessions both with and without the presence of management. Our Board committees also generally meet in executive session at the end of each committee meeting.
Executive and Director Compensation Processes
The agenda for each meeting of the Compensation Committee is usually developed by the Chair of the Compensation Committee in consultation with our Chief Executive Officer. The Compensation Committee meets regularly in executive session. From time to time, various members of management and other employees as well as outside advisors or consultants may be invited by the Compensation Committee to make presentations, to provide financial or other background information or advice, or to otherwise participate in Compensation Committee meetings. No officer may participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding the compensation for such officer or employee. Our Chief Executive Officer provides recommendations to our Compensation Committee with respect to executive and employee compensation, other than herhis own
compensation. The Compensation Committee takes into consideration Ms. Lurker’sDr. Duker’s input in granting annual bonuses or equity awards and setting compensation levels.
The charter of the Compensation Committee grants the Compensation Committee full access to all of our books, records, facilities, and personnel, as well as the authority to obtain, at our expense, advice and assistance from internal and external legal, accounting, or other advisors and consultants and other external resources that the Compensation Committee considers necessary or appropriate in the performance of its duties. In particular, the Compensation Committee has the authority to retain compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant’s reasonable fees and other retention terms.
During 2022,2023, the Compensation Committee retained Radford, part of the RewardsAon’s Human Capital Solutions practice, ata division of Aon, plc (Aon), as its independent consultant to assist in evaluating our executive compensation programs and practices and to make recommendations regarding compensation for the year ended December 31, 2022.2023. During this process, Radford:Aon:
None of Radford, Aon or their affiliates provides other services to us. The Compensation Committee assessed the independence of RadfordAon pursuant to SEC rules and concluded that no conflict of interest existed that would prevent RadfordAon from independently representing the
14
Compensation Committee. The Compensation Committee has sole responsibility for the selection, engagement, removal and compensation of its compensation consultant.
The Compensation Committee may form and delegate any or all of its duties or responsibilities to a subcommittee of the Compensation Committee, to the extent consistent with our Certificate of Incorporation, bylaws and applicable laws and rules of markets in which our securities then trade.
Board Committees
The Board has four standing committees: the Audit Committee, the Compensation Committee, the Governance and Nominating Committee and the Science Committee. Each standing committee has a written charter. Each of the Audit Committee, the Compensation Committee and the Governance and Nominating Committee is comprised entirely of independent directors. The Science Committee is currently comprised of independent directors;directors and Dr John Landis, who serves as both a consultant leading the Company GMP and also as a Board member; however, it may also in the future include members of our R&D organization and other members of executive management in accordance with its charter. While each committee has designated responsibilities, the committees act on behalf of the entire Board and regularly report on their activities to the entire Board. Details concerning the role and structure of the Board and each Board committee are contained in the Corporate Governance Guidelines and the committee charters, available on the “Investor” section of our website at www.eyepointpharma.com under “Corporate Governance.”
Audit Committee
The Audit Committee is responsible for assisting the Board with oversight of our accounting and financial reporting processes, including but not limited to (i)(a) our audit program; (ii)(b) the integrity of our financial statements; (iii)(c) the review and assessment of the qualifications and independence of our independent registered public accounting firm; and (iv)(d) the preparation of reports required of the Audit Committee under the rules of the SEC. The Audit Committee is also responsible for (i) overseeing the establishment of effective internal controls and procedures intended to ensure the Company’s compliance with relevant accounting standards, financial reporting procedures and applicable laws and regulations, (ii) overseeing and monitoring the Company’s compliance with legal and regulatory requirements, and (iii) overseeing the Company’s risk assessment and risk management policies and programs, including matters relating to cybersecurity.
More specifically, the Audit Committee’s responsibilities include:
15
The members of the Audit Committee are Ms. DiCicco (Chair), Dr. Guyer, Ms. Zaderej and Ms. Zaderej.Mr. Duty. Ms. DiCicco, Dr. Guyer, and Ms. Zaderej, and Mr. Duty were members of the Audit Committee during the year ended December 31, 2022.2023.
The Board has determined that all members of the Audit Committee are independent for purposes of service on the Audit Committee as provided in SEC and Nasdaq rules, as applicable. The Board also has determined that Ms. DiCicco, Dr. Guyer, and Ms. Zaderej, and Mr. Duty are audit"audit committee financial experts.experts" as defined under SEC rules.
The Audit Committee met fourfive times during the year ended December 31, 2022.2023.
Compensation Committee
The Compensation Committee is responsible for (i) discharging the Board’s responsibilities relating to executive compensation, (ii) overseeing our compensation and employee benefits plans and practices, including incentive, equity-based and other compensatory plans in which executive officers and key employees participate, (iii) producing a report on executive compensation as required by the SEC, and (iv) overseeing our approach and management of risks related to human capital. More specifically, the Compensation Committee’s responsibilities include:include, but are not limited to:
16
The members of the Compensation Committee are Dr. Guyer (Chair), Dr. Ando, and Ms. DiCicco. Dr. Guyer, Dr. Ando, and Ms. DiCicco were members of the committee during the year ended December 31, 2022.2023.
The Board has determined that all members of the Compensation Committee are independent for purposes of service on the Compensation Committee as provided in SEC and Nasdaq rules, as applicable.
The Compensation Committee met four times during the year ended December 31, 2022.2023.
The processes and procedures followed by our Compensation Committee in considering and determining executive and director compensation are described above under “Corporate Governance and Board Matters—Board Leadership Structure, Processes, and Role in Risk Oversight—Executive and Director Compensation Processes.”
Governance and Nominating Committee
The Governance and Nominating Committee is responsible for (i) identifying and recommending to the Board individuals qualified to serve as directors and advising the Board with respect to Board composition and procedures, (ii) overseeing the evaluation of the Board and the committees, (iii) developing and maintaining our corporate governance policies, and (iv) overseeing our activities relating to corporate social responsibility and environmental and sustainability matters. The Governance and Nominating Committee has periodically engaged third parties to identify and evaluate candidates qualified to serve as our directors and may continue to do so in the future. More specifically, the Governance and Nominating Committee’s responsibilities include:
17
The members of the Governance and Nominating Committee are Dr. Ando (Chair), Ms. DiCicco, and Dr. Guyer. Each of Dr. Ando, Ms. DiCicco, and Dr. Guyer was a member of the committee during the year ended December 31, 2022.2023.
The Board has determined that all members of the Governance and Nominating Committee are independent for purposes of service on the Governance and Nominating Committee as provided in SEC and Nasdaq rules, as applicable.
The Governance and Nominating Committee met four times during the year ended December 31, 2022.2023.
18
Science Committee
The Science Committee is responsible for assisting the Board in ensuring that our research and development organization is optimized to support the strategic goals and making recommendations to the Board on key strategic and tactical issues relating to our research and development activities. To accomplish this purpose, the Committee reviews and monitors the science, processes, procedures, and infrastructure underlying the Company’s major discovery and development programs. More specifically, the Science Committee’s responsibilities include:
The current members of the Science Committee are Dr. Landis (Chair), Dr. Ando, Dr. Guyer, and Dr. Adamis. Each of Dr. Landis, Dr. Ando, Dr. Guyer, and Dr. Adamis was a member of the committee during the year ended December 31, 2022.2023.
The Science Committee met four times during the year ended December 31, 2022.2023.
Attendance at Board and Committee Meetings
The Board met four times during the year ended December 31, 2022. Each2023. Except for Mr. Liu, each of the directors who served during the year ended December 31, 20222023 are standing for election in 2023.2024. Each of the directors who served the full year attended at least 75% of the aggregate of the total number of meetings of the Board and of the committees on which he or she served (during the period that each such director served). Our corporate governance guidelines encourage, but do not require our directors to attend annual meetings of stockholders. EachAll but one of the directors who was serving as a director as of the 20222023 Annual Meeting attended the 20222023 Annual Meeting, either in person or by telephone.
Stockholder Nominations for Director
The Governance and Nominating Committee will consider written stockholder recommendations for candidates for the Board, which recommendations should be delivered or mailed, postage prepaid, to:
Company Secretary
EyePoint Pharmaceuticals, Inc.
480 Pleasant Street, Suite C400
Watertown, MA 02472
United States
Stockholder recommendations must include certain relevant information concerning the candidate, the stockholder making the recommendation and any beneficial owner on whose behalf the recommendation is made. The required information is set forth in our
19
Stockholder Nomination Policy, available on the “Investor” section of our website at www.eyepointpharma.com under “Corporate Governance – Governance Overview.”
The Governance and Nominating Committee will evaluate candidates for director who are recommended by stockholders on the same basis as candidates recommended by other sources. Considerations include the Governance and Nominating Committee’s discretionary assessment of the skills represented and required on the Board, and an evaluation of candidates against the standards and qualifications set forth in our Corporate Governance Guidelines and criteria approved by the Board from time to time. We do not have a formal policy with respect to diversity, although we seek to have a Board that reflects a range of talents, ages, skills, viewpoints, professional experience, educational backgrounds, expertise, genders, and ethnicities. The Governance and Nominating Committee will determine whether to interview any candidate in its sole discretion.
Stockholder Communications with Directors
Stockholders and other interested parties may communicate directly with the Board, the independent directors, the Chair of the Board, any other group of directors or any individual director. The required information is set forth in our Policy Regarding Stockholder Communications With Directors, available on the “Investor” section of our website at www.eyepointpharma.com under “Corporate Governance – Governance Overview.” Any such written communications should be addressed to the relevant group or individual and sent to the following address:
Name(s) of Director(s), Group of Directors or Board of Directors
c/o Company Secretary
EyePoint Pharmaceuticals, Inc.
480 Pleasant Street, Suite C400
Watertown, MA 02472
United States
Our Company Secretary will forward such communications to the relevant group or individual at or prior to the next meeting of the Board.
Code of Business Conduct
We have adopted a Code of Business Conduct applicable to each of our officers, directors and employees, and consultants and contractors to, us and our subsidiaries, including our principal executive officer and principal financial officer. The Code of Business Conduct is a set of policies on key integrity issues that requires our representatives to act ethically and legally. It includes policies with respect to conflicts of interest, corporate & social responsibility, compliance with laws, insider trading, corporate opportunities, competition and fair dealing, discrimination and harassment, health and safety, record-keeping, confidentiality, protection and proper use of assets, payments to government personnel, and reports to and communications with the SEC and the public.
We review the Code of Conduct annually and update it as appropriate. We intend to disclose any future amendments to, or waivers from, the Code of Business Conduct that affect our directors or senior financial and executive officers within four business days of the amendment or waiver by posting such information on the “Investor” section of our website at www.eyepointpharma.com under “Corporate Governance—Governance Overview.”
Insider Trading, Hedging and Pledging Prohibition
Under our SecuritiesInsider Trading Policy, our directors, officers, employees, consultants, and contractors (and each such individual’s family members who reside with them, anyone else who lives in their household and any family members who do not live in their household but whose transactions in our securities are directed by the insider or are subject to the insider’s influence or control) are prohibited from engaging the following transactions at any time: (i) engaging in short sales of our securities; (ii) trading in put options, call options or other derivative securities on an exchange or in any other organized market; (iii) engaging in hedging or monetization transactions, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds; and (iv) holding our securities in a margin account or otherwise pledging our securities as collateral for loan. Our full insider trading policy is on our website, www.eyepointpharma.com. The information contained on the Company's website is not deemed incorporated by reference in this proxy statement.
Audit Committee Report
As more fully described in its charter, the Audit Committee oversees our financial reporting process on behalf of the Board. Our management is responsible for our financial reporting process, including assuring that we develop and maintain adequate financial
20
controls and procedures, and assess compliance therewith. Our independent registered public accounting firm, Deloitte & Touche LLP (Deloitte) is responsible for performing an audit of the effectiveness of our internal control over financial reporting in conjunction with an audit of our consolidated financial statements in accordance with standards of the Public Company Accounting Oversight Board (United States) (PCAOB), and issuing its opinion on the financial statements and the effectiveness of internal control over financial reporting.
The Audit Committee reviewed and discussed our audited consolidated financial statements for the fiscal year ended December 31, 20222023 with our management and Deloitte. The Audit Committee also reviewed and discussed with Deloitte our audited consolidated financial statements and the matters required to be discussed by the applicable requirements of the PCAOB. The Audit Committee met with Deloitte, with and without management present, to discuss the results of their examinations, other areas of oversight relating to the financial reporting and audit process that the Audit Committee determined appropriate, their evaluation of our internal controls, and the overall quality of our financial reporting.
The Audit Committee discussed with Deloitte the firm’s independence and received from Deloitte and reviewed the written disclosures and the letter required by PCAOB Ethics and Independence Rule 3526 (Communication with Audit Committees Concerning Independence). The Audit Committee considered whether Deloitte’s provision of non-audit services to us is compatible with Deloitte’s independence and concluded that Deloitte is independent from our company and our management.
Based on the above-referenced reviews and discussions with our management and Deloitte, the Audit Committee recommended to the Board that our audited consolidated financial statements be included in our Annual Report on Form 10-K for the year ended December 31, 2022,2023, for filing with the SEC.
| Submitted by the members of the |
| Audit Committee |
|
Wendy DiCicco (Chair)
David Guyer
Karen Zaderej Stuart Duty |
RELATED PARTY TRANSACTIONS
Policy Regarding Transactions with Related Persons
We maintain a written “Policy Regarding Related Person Transactions."Related Party Transaction Policy.” Under this policy, the Audit Committee or, in time sensitive instances, the Chair of the Audit Committee, has responsibility for reviewing and approving or ratifying any transaction in which we and any of our directors, director nominees, executive officers or 5% stockholders and their immediate family members are participants, or in which such persons have a direct or indirect material interest, as provided under SEC rules. In reviewing transactions, the committee or the Chair considers all of the relevant facts and circumstances, and approves only those transactions that the committee or the Chair in good faith determines to be in, or not inconsistent with, the best interests of us and our stockholders. Except as otherwise disclosed below, there were no such related-person transactions since January 1, 2021.2022.
Transactions with Related Persons
Ocumension Transactions
Licensing Transactions
In November 2018, we entered into an exclusive license agreement with Ocumension for the development and commercialization of our three-year micro insert using the Durasert® technology for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (YUTIQ in the U.S.) in Mainland China, Hong Kong, Macau, and Taiwan.
In August 2020, we entered into a Memorandum of Understanding (2020 MOU) pursuant to which we received a one-time non-refundable payment of $9.5 million (Accelerated Milestone Payment) from Ocumension as a full and final payment of the combined remaining development, regulatory, and sales milestone payments under our license agreements with Ocumension for the treatment of
21
chronic non-infectious uveitis affecting the posterior segment of the eye and for the treatment of post-operative inflammation following ocular surgery. Upon payment of the Accelerated Milestone Payment, the remaining $11.75 million in combined remaining development and sales milestone payments under our original license agreement with Ocumension upon the achievement by Ocumension of (i) remaining development and regulatory milestones of $6.25 million and commercial sales-based milestones of $3.0 million for the development and commercialization of our three-year micro insert using the Durasert technology for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and (ii) $6.0 million upon the achievement by Ocumension of certain prescribed development and regulatory milestones, and $6.0 million commercial sales-based milestones for the development and commercialization in Mainland China, Hong Kong, Macau and Taiwan of DEXYCU® for the treatment of post-operative inflammation following ocular surgery, totaling up to $21.25 million, were permanently extinguished and will no longer be due to us. In exchange, Ocumension also received exclusive rights to develop and commercialize YUTIQ® and DEXYCU products under its own brand names in South Korea and other jurisdictions across Southeast Asia in Brunei, Burma (Myanmar), Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, and Vietnam, at its own cost and expense with us supplying product for clinical trials and commercial sale.
YUTIQ received regulatory approval in China in June 2022, and is now being marketed and sold commercially by Ocumension in China. Pursuant to our agreements with Ocumension, we are entitled to receive mid-single digit sales-based royalties on their net sales of YUTIQ.
Other than a fixed number of hours of technical assistance support to be provided at no cost by us, Ocumension is responsible for all development, regulatory and commercial costs, including any additional technical assistance requested.
Equity Financing
On December 31, 2020, we entered into the Share Purchase Agreement with Ocumension, pursuant to which we offered and sold to Ocumension 3,010,722 shares of our common stock at a purchase price of $5.2163 per share, resulting in gross proceeds of approximately $15.7 million. On December 31, 2020, we entered into the Voting Agreement with Ocumension, EWHP and EWHP-A. Pursuant to the Voting Agreement, for so long as Ocumension owns a number of shares of our common stock equal to at least 75% of the shares of our common stock it acquired on December 31, 2020, and subject to compliance with applicable law and our guidelines with respect to the nomination of directors, Ocumension is entitled to designate for nomination one person (Investor Designee) to serve as a member of our Board, the Science Committee and certain other ad-hoc committees of the Board. Notwithstanding the foregoing, in accordance with Nasdaq Listing Rule 5640, Ocumension will not be entitled to designate for nomination any person to serve as a member of our Board if, at any time, Ocumension owns a number of shares of our common stock representing less than 5%
of the shares of our common stock outstanding. Pursuant to the Voting Agreement, for so long as EWHP and EWHP-A beneficially own at least 10% of the outstanding shares of our common stock, EWHP and EWHP-A agreed to vote in favor of the Investor Designee at each election of the Board. The initial Investor Designee is Ye (Victor) Liu.
Director and Officer Indemnification Agreements
We have entered into indemnification agreements with our directors and executive officers. In general, these agreements provide that we will indemnify the director or executive officer to the fullest extent permitted by law for claims arising in his or her capacity as a director or executive officer of our company or in connection with their service at our request for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for indemnification and establishes certain presumptions that are favorable to the director or executive officer.
We maintain a general liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.
STOCK OWNERSHIP
Stock Ownership of Directors, Director Nominees, Officers and Principal Stockholders
At the close of business on April 21, 2023,23, 2024, there were 34,301,92652,084,148 shares of our common stock issued and outstanding and entitled to vote. On April 21, 2023,23, 2024, the closing price of our common stock as reported on the Nasdaq Global Market was $9.00$17.57 per share. The following table sets forth certain information relating to the beneficial ownership of our common stock as of April 21, 202323, 2024 by:
Beneficial ownership is determined in accordance with the rules of the SEC as indicated in the footnotes to the table below.
Unless otherwise indicated, the address for each of the beneficial owners listed below is: c/o EyePoint Pharmaceuticals, Inc., 480 Pleasant Street, Suite C400, Watertown, MA 02472, United States.
Beneficial Owner |
| Aggregate |
|
| Percent of |
| ||
Greater Than 5% Stockholder: |
|
|
|
|
|
| ||
EW Healthcare(2)(3) |
|
| 4,190,921 |
|
|
| 12.22 | % |
Ocumension Therapeutics(4) |
|
| 3,010,722 |
|
|
| 8.78 | % |
Franklin Resources(5) |
|
| 5,774,509 |
|
|
| 16.83 | % |
Suvretta Capital Management(6) |
|
| 3,436,897 |
|
|
| 9.99 | % |
RA Capital Management(7) |
|
| 3,434,506 |
|
|
| 9.99 | % |
Adage Capital(8) |
|
| 1,950,000 |
|
|
| 5.68 | % |
Executive Officers and Directors: |
|
|
|
|
|
| ||
Göran Ando |
|
| 50,500 |
|
| * |
| |
Nancy Lurker(9) |
|
| 711,995 |
|
|
| 2.04 | % |
John Landis |
|
| 48,750 |
|
| * |
| |
David Guyer |
|
| 40,750 |
|
| * |
| |
Wendy DiCicco |
|
| 40,750 |
|
| * |
| |
Ye Liu(4) |
|
| 3,010,722 |
|
|
| 8.78 | % |
Anthony P. Adamis |
|
| — |
|
| * |
| |
Karen Zaderej |
|
| — |
|
| * |
| |
Jay Duker |
|
| 219,859 |
|
| * |
| |
Michael Pine |
|
| 38,575 |
|
| * |
| |
All current directors and executive officers |
|
| 4,645,782 |
|
|
| 13.05 | % |
22
Beneficial Owner |
| Aggregate |
|
| Percent of |
| ||
Greater Than 5% Stockholder: |
|
|
|
|
|
| ||
Cormorant Asset Management(2) |
|
| 7,475,000 |
|
|
| 14.35 | % |
Adage Capital(3) |
|
| 5,156,299 |
|
|
| 9.90 | % |
Suvretta Capital Management(4) |
|
| 5,147,756 |
|
|
| 9.68 | % |
Franklin Resources(5) |
|
| 4,640,651 |
|
|
| 8.91 | % |
RA Capital Management(6) |
|
| 3,095,136 |
|
|
| 5.94 | % |
Executive Officers and Directors: |
|
|
|
|
|
| ||
Göran Ando |
|
| 91,100 |
|
| * |
| |
Jay Duker(7) |
|
| 434,137 |
|
| * |
| |
Nancy Lurker(8) |
|
| 1,018,781 |
|
|
| 1.93 | % |
John Landis |
|
| 87,850 |
|
| * |
| |
David Guyer |
|
| 79,850 |
|
| * |
| |
Wendy DiCicco |
|
| 79,850 |
|
| * |
| |
Ye Liu(9) |
|
| 100,221 |
|
| * |
| |
Anthony P. Adamis |
|
| 48,433 |
|
| * |
| |
Karen Zaderej |
|
| 48,433 |
|
| * |
| |
George Elston |
|
| 271,438 |
|
| * |
| |
Dario Paggiarino(10) |
|
| 304,894 |
|
| * |
| |
Stuart Duty |
|
| — |
|
| * |
| |
All current directors and executive officers |
|
| 2,564,987 |
|
|
| 4.74 | % |
* Represents holdings of less than 1% of our outstanding common stock.
23
Equity Compensation Plan Information
The following table provides information about the securities authorized for issuance under the Company’s equity compensation plans as of December 31, 2022:2023:
Plan category |
| Number of securities |
| Weighted-average |
| Number of securities |
| |
Equity Compensation plans approved by |
| 3,924,675 | (1) |
| $13.51 |
| 2,373,460 | (5) |
Equity Compensation plans not approved by |
| 667,050 | (3) |
| 15.21 |
| — |
|
Total |
| 4,591,725 |
|
| $13.79 |
| 2,373,460 |
|
Plan category |
| Number of securities |
| Weighted-average |
| Number of securities |
| |
Equity Compensation plans approved by |
| 6,875,970 | (1) |
| $9.31 |
| 2,402,485 | (5) |
Equity Compensation plans not approved by |
| 761,989 | (3) |
| 14.85 |
| — |
|
Total |
| 7,637,959 |
|
| $9.98 |
| 2,402,485 |
|
EXECUTIVE OFFICER AND DIRECTOR COMPENSATION
Our named executive officers for the year ended December 31, 20222023 are Nancy Lurker, our Chief Executive Officer, Dr. Jay Duker, our current President and Chief OperatingExecutive Officer, Nancy Lurker, our former President and Chief Executive Officer and Michael Pine,current Executive Vice Chair of the Board, George
24
Elston, our Executive Vice President and Chief Corporate DevelopmentFinancial Officer, and StrategyDr. Dario Paggiarino, our former Senior Vice President and Chief Medical Officer, who we collectively refer to as our Named Executive Officers.
Summary Compensation Table
The following table and footnotes provide information regarding the compensation of our Named Executive Officers for the year ended December 31, 20222023 and the year ended December 31, 2021:2022:
Executive Name and Principal |
| Year |
| Salary |
| Bonus |
| Stock |
| Option |
| Non-Equity |
| All Other |
| Total |
|
Nancy Lurker |
| 2022 |
| 643,831 |
| — |
| 607,800 |
| 1,636,376 |
| 532,188 |
| 25,023 |
| 3,445,218 |
|
Chief Executive Officer |
| 2021 |
| 603,233 |
| — |
| 690,638 |
| 1,822,885 |
| 490,702 |
| 15,910 |
| 3,623,368 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jay Duker |
| 2022 |
| 515,000 |
| — |
| 212,730 |
| 1,002,207 |
| 308,750 |
| 24,751 |
| 2,063,438 |
|
President and Chief Operating Officer |
| 2021 |
| 268,667 |
| 175,000 |
| 370,646 |
| 2,328,478 | (6) | 168,684 |
| 2,605 |
| 3,314,080 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Michael Pine |
| 2022 |
| 410,577 |
| 108,000 |
| — |
| 849,388 |
| 224,438 |
| 21,838 |
| 1,614,241 |
|
Chief Corporate Development and Strategy Officer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Executive Name and Principal |
| Year |
| Salary |
|
| Bonus |
|
| Stock |
|
| Option |
|
| Non-Equity |
|
| All Other |
|
| Total |
|
| |||||||
Jay Duker |
| 2023 |
|
| 614,064 |
|
|
| 47,225 |
| (1) |
| 658,859 |
|
|
| 961,793 |
|
|
| 605,877 |
|
|
| 27,328 |
|
|
| 2,915,146 |
|
|
President and Chief Executive Officer |
| 2022 |
|
| 515,000 |
|
|
| — |
|
|
| 212,730 |
|
|
| 1,002,207 |
|
|
| 308,750 |
|
|
| 24,751 |
|
|
| 2,063,438 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Nancy Lurker |
| 2023 |
|
| 570,025 |
|
|
| 49,242 |
| (1) |
| 1,038,477 |
|
|
| 1,479,628 |
|
|
| 574,486 |
|
|
| 25,527 |
|
|
| 3,737,385 |
|
|
Former President and Chief Executive Officer; Current Executive Vice Chair of the Board of Directors |
| 2022 |
|
| 643,831 |
|
|
| — |
|
|
| 607,800 |
|
|
| 1,636,376 |
|
|
| 532,188 |
|
|
| 25,023 |
|
|
| 3,445,218 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
George Elston |
| 2023 |
|
| 487,824 |
|
|
| 24,938 |
| (1) |
| 282,912 |
|
|
| 591,869 |
|
|
| 367,141 |
|
|
| 25,441 |
|
|
| 1,780,125 |
|
|
Executive Vice President and Chief Financial Officer |
| 2022 |
|
| 469,062 |
|
|
| — |
|
|
| 177,275 |
|
|
| 477,277 |
|
|
| 253,089 |
|
|
| 23,941 |
|
|
| 1,400,644 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Dario Paggiarino(7) |
| 2023 |
|
| 492,376 |
|
|
| 72,975 |
| (2) |
| 149,487 |
|
|
| 209,034 |
|
|
| 349,594 |
|
|
| 24,690 |
|
|
| 1,298,156 |
|
|
Former SVP, Chief Medical Officer |
| 2022 |
|
| 472,344 |
|
|
| — |
|
|
| 177,275 |
|
|
| 477,277 |
|
|
| 255,450 |
|
|
| 23,974 |
|
|
| 1,406,320 |
|
|
Narrative Disclosure to Summary Compensation Table
2022 Fiscal Year Base Salaries
In 2022,2023, the initial annual base salary was $655,000$581,000 for Dr. Duker, $695,000 for Ms. Lurker, $520,000$492,561 for Mr. Elston, and $497,156 for Dr. Paggiarino. On July 10, 2023 Dr. Duker was appointed President and $420,000 for Mr. Pine.CEO with a base salary of $650,000 and Ms. Lurker was appointed Executive Vice Chair of the Board with an adjusted base salary of $455,000. For the fiscal year ending December 31, 2023,2024, the Compensation Committee approved salary increases of 4% for each of our Named Executive Officers, with effect from April 1, 2023.
25
2024. The resulting annual base salaries are as follows: $695,000$676,000 for Dr. Duker, $473,200 for Ms. Lurker, (inclusive of a $13,800 market adjustment) and $446,800$512,304 for Mr. Pine (inclusive of a $10,000 market adjustment).Elston, and $517,088 for Dr. Duker's salary was set at $581,000, which is inclusive of his merit increase, upon his promotion to President and COO effective January 3, 2023.Paggiarino.
20222023 Fiscal Year Non-Equity Incentive Plan Compensation and Discretionary Bonuses
Each of our executive officers is eligible to receive an annual performance bonus based on the achievement of corporate goals, as determined by our Board of Directors, and individual performance goals, as recommended by our Chief Executive Officer, for executives other than himself, and approved by the Compensation Committee. The performance bonus for our Chief Executive Officer and for our PresidentExecutive Vice Chair is weighted 100% for achievement of our corporate goals, whereas the performance bonus for our other Named Executive Officers is weighted 75% for corporate goal achievement and 25% for individual goal achievement. The annual target bonus as a percentage of base salary was established at 65%60% for Dr. Duker (effective July 10, 2024 as CEO, 55% prior to such date), 45% for Ms. Lurker 55% for Dr. Duker(effective July 10, 2024 as Executive Vice Chair, 65% prior to such date), and 45% for each of Mr. Pine.Elston and Dr. Paggiarino.
The corporate goals were establishedpre-established by the Compensation Committee and the full Board of Directors for the year ended December 31, 2022.2023. The corporate goals for 20222023 consisted primarily of: (i) initiationfull enrollment and first patienttop line data release in the DAVIO 2 EYP-1901 Phase 2 clinical trial; (ii) full enrollment in DAVIO andof the PAVIA EYP-1901 Phase 2 clinical trials; (ii)trial; (iii) minimum cash target at year-end; and (iii) YUTIQ revenue targets.(iv) EYP-1901 clinical trial material readiness. The Compensation Committee approved a corporate performance score of 125% as recommended by our Chief Executive Officer,175% (the maximum permitted under the pre-established corporate goals) for the year ended December 31, 2022.2023 on the basis that all of the 2023 corporate goals were achieved to the maximum amount permitted thereunder. The Compensation Committee also approved an additional 15% added to the corporate performance score for achievement of a minimum upfront payment in the closing of the out-license of the YUTIQ® franchise to Alimera Sciences Inc. Mr. Elston and Dr. Duker and Mr. PinePaggiarino were given individual performance scores of 138% and 100%., respectively. Actual bonus amounts earned with respect to the 125%total 175% corporate goal achievement and the individual performance scores (as applicable) for the year ended December 31, 20222023 are reflected in the “Non-Equity Incentive Plan Compensation” column and the additional 15% is reflected in the Bonus column of the Summary Compensation Table above.
20222023 and 20232024 Fiscal Year Equity Award Grants
On February 9, 2022, the Compensation Committee approved the following option grants to our Named Executive Officers: 240,000 options to Ms. Lurker and 85,000 to Dr. Duker. The exercise price of these options is $10.13 per share, the closing price of the Company’s common stock on the date of Compensation Committee approval, and the options vested as to 25% of the shares subject to the option after one year and then will vest ratably over 36 months thereafter. In addition, the Compensation Committee approved the following RSUs to our Named Executive Officers: 60,000 to Ms. Lurker and 21,000 to Dr. Duker with pro rata annual vesting over three years.
On December 14, 2022, the Compensation Committee approved the following option grants to our Named Executive Officers: 124,755 options to Dr. Duker, 450,800 options to Ms. Lurker, 124,75591,655 options to Dr. DukerMr. Elston, and 91,655 options to Mr. Pine.Dr. Paggiarino. The grants were made on January 6, 2023 with an exercise price of $3.26 per share, the closing price of the Company’s common stock on the date of grant, and the options will vest as to 25% of the total shares subject to the option on the one year anniversary of the grant date and then ratably over 36 months thereafter, provided that the executive maintains continuous employment with the Company during the vesting period. In addition, the Compensation Committee approved the following RSUs to be granted on January 6, 2023, to our Named Executive Officers: 62,380 RSUs to Dr. Duker, 225,400 RSUs to Ms. Lurker, 45,855 RSUs to Mr. Elston, and 45,855 RSUs to Dr. Paggiarino, all with pro rata annual vesting over three years.
On July 10, 2023, the Compensation Committee and the full Board of Directors approved the following equity grants to Dr. Duker and Ms. Lurker, in connection with amendments to their respective employment agreements and in conjunction with their appointments to the positions of President and CEO for Dr. Duker and Executive Vice Chair for Ms. Lurker, effective July 10, 2023: 100,000 options to Dr. Duker and 66,666 options to Ms. Lurker, each with an exercise price of $9.11 per share, the closing price of the Company’s common stock on the date of grant, and the options will vest as to 25% of the total shares subject to the option on the one year anniversary of the grant date and then ratably over 36 months thereafter, provided that the executive maintains continuous employment with the Company during the vesting period. 50,000 RSUs to Dr. Duker and 33,334 RSUs to Ms. Lurker, each with pro rata annual vesting over three years.
On December 13, 2023, the Compensation Committee approved the following option grants to our Named Executive Officers: 180,000 options to Dr. Duker, 77,000 options to Ms. Lurker, 90,000 options to Mr. Elston, and 42,000 options to Dr. Paggiarino. The grants were made on January 5, 2024 with an exercise price of $20.40 per share, the closing price of the Company’s common stock on the date of grant, and the options will vest as to 25% of the shares subject to the option after one year and then ratably over 36 months thereafter. In addition, on December 13, 2023, the Compensation Committee approved the grant of the following RSUs to be granted on January 5, 2024, to our Named Executive Officers: 225,40090,000 RSUs to Dr. Duker, 38,000 RSUs to Ms. Lurker, 62,38045,000 RSUs to Mr. Elston, and 21,000 RSUs to Dr. Duker and 45,855 to Mr. PinePaggiarino, all with pro rata annual vesting over three years. These RSU grants are subject to the approval of Annual Meeting Proposal No. 2, as discussed further below, to approve our 2023 Long-Term Incentive Plan.
401(k) Plan
We maintain a defined contribution 401(k) retirement plan (401(k) Plan) for all employees in the United States, including our Named Executive Officers. Employees are eligible to participate in the 401(k) Plan in the month following their date of hire. Under the terms
26
of the 401(k) Plan, participating employees may defer up to 100% of their pre-tax salary provided that such deferral is not in excess of the applicable statutory limits within any calendar year. The Company matches 100% of employee contributions up to a maximum of
6% of salary and bonus compensation, subject to annual Internal Revenue Service limits. Employee contributions and our company matching contributions to the 401(k) Plan vest immediately.
Employee Benefits and Perquisites
Our Named Executive Officers are eligible to participate in our health and welfare programs to the same extent as all full-time employees generally and are entitled to 20 days of annual paid time off in accordance with our vacation policy. We also provide our Named Executive Officers (NEO's) and other employees with group term life insurance and short and long-term disability (LTD) insurance at our expense. In addition to the regular LTD insurance, we offer Supplemental LTD insurance to our NEO's. Under the terms of the LTD policies, premiums paid by the Company are included in the employee’s taxable income, provided that any benefits payable to an employee under the LTD policy are not subject to income tax.
Employment Agreements
Jay Duker, who was appointed as our President and CEO on July 10, 2023 (he previously served as our Chief Operating Officer, and prior to that, served as Chief Strategic Scientific Officer), is employed under an employment agreement with us that provides for a base salary, a discretionary annual cash bonus based on the achievement of Company and individual performance goals, discretionary equity incentives, and severance payments as described further below under Additional Narrative Disclosure—Termination-Based Compensation.
Nancy Lurker, who was appointed our Chief Executive Officer since September 15, 2016,Vice Chair of the Board of Directors on July 10, 2023 (she previously served as our President and Chief Executive Officer) is employed under an employment agreement with us that provides for a minimum base salary, a discretionary annual cash bonus based on the achievement of Company performance goals, discretionary equity incentives and severance payments as described further below under Additional Narrative Disclosure—Termination-Based Compensation.
Jay Duker,George Elston, who was appointed asbecame our Chief OperatingFinancial Officer (COO) on November 1, 2021 (he previously served as our Chief Strategic Scientific Officer) and as our President and COO effective January 3, 2023,14, 2019, is employed under an employment agreement with us that provides for a minimum base salary, a discretionary annual cash bonus based on the achievement of Company and individual performance goals, discretionary equity incentives, and severance payments as described further below underAdditional Narrative Disclosure—Termination-Based Compensation.
Michael Pine, who became
Dario Paggiarino, our former Chief Corporate DevelopmentMedical Officer was hired on August 1, 2016, and Strategy Officer on January 10, 2022, iswas employed under an employment agreement with us that providesprovided for a base salary, a discretionary annual cash bonus based on the achievement of the Company and individual performance goals, discretionary equity incentives, and severance payments as described further below underAdditional Narrative Disclosure—Termination-Based Compensation. Dr. Paggiarino's employment with the Company terminated involuntarily effective March 29, 2024.
27
Outstanding Equity Awards at 20222023 Year End
The following table and footnotes provide information concerning outstanding equity awards for our Named Executive Officers as of December 31, 2022:2023:
|
| Option Awards |
| Stock Awards | |||||||||||||||||||||||||
|
| Number of Securities |
| Option |
|
| Option |
| Number of |
| Market value |
|
| Equity |
| Equity | |||||||||||||
Name |
| Exercisable |
|
| Unexercisable |
|
|
| ($) |
|
| Date |
| (#) |
| ($)(6) |
|
| (#) |
| ($) | ||||||||
Nancy Lurker |
|
| 85,000 |
|
|
| — |
|
|
|
| 36.3000 |
|
| 09/15/26 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
| 24,000 |
|
|
| — |
|
|
|
| 17.7000 |
|
| 06/27/27 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 54,000 |
|
|
| — |
|
|
|
| 20.4000 |
|
| 06/14/28 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 89,126 |
|
|
| 3,874 |
| (1) |
|
| 26.5000 |
|
| 02/21/29 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 52,988 |
|
|
| 21,812 |
| (1) |
|
| 12.9000 |
|
| 02/28/30 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 97,945 |
|
|
| 115,755 |
| (1) |
|
| 13.1300 |
|
| 02/09/31 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| — |
|
|
| 240,000 |
| (1) |
|
| 10.1300 |
|
| 02/09/32 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
|
|
| 95,067 |
| (4) |
|
| 332,735 |
|
|
|
|
|
| ||||
Jay Duker |
|
| 4,000 |
|
|
| — |
|
|
|
| 31.7000 |
|
| 09/26/26 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
| 2,666 |
|
|
| — |
|
|
|
| 19.5000 |
|
| 06/21/28 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 4,000 |
|
|
| — |
|
|
|
| 26.5000 |
|
| 02/21/29 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 3,350 |
|
|
| — |
|
|
|
| 12.9000 |
|
| 02/28/30 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 15,105 |
|
|
| 9,895 |
| (2) |
|
| 7.2000 |
|
| 07/13/30 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 27,637 |
|
|
| 32,663 |
| (2) |
|
| 13.1300 |
|
| 02/09/31 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 64,919 |
|
|
| 174,781 |
| (2)(7) |
|
| 11.4700 |
|
| 11/01/31 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| — |
|
|
| 85,000 |
| (2) |
|
| 10.1300 |
|
| 02/09/32 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| — |
|
|
| 65,300 |
| (2) |
|
| 9.4500 |
|
| 09/06/32 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
|
|
| 30,934 |
| (5) |
|
| 108,269 |
|
|
|
|
|
| ||||
Michael Pine |
|
| — |
|
|
| 100,000 |
| (3) |
|
| 12.6200 |
|
| 01/10/32 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| — |
|
|
|
| — |
|
|
|
|
|
|
28
|
| Option Awards |
| Stock Awards | |||||||||||||||||||||||||
|
| Number of Securities |
| Option |
|
| Option |
| Number of |
| Market value |
|
| Equity |
| Equity | |||||||||||||
Name |
| Exercisable |
|
| Unexercisable |
|
|
| ($) |
|
| Date |
| (#) |
| ($)(9) |
|
| (#) |
| ($) | ||||||||
Jay Duker |
|
| 4,000 |
|
|
| — |
|
|
|
| 31.7000 |
|
| 09/26/26 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
| 2,666 |
|
|
| — |
|
|
|
| 19.5000 |
|
| 06/21/28 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 4,000 |
|
|
| — |
|
|
|
| 26.5000 |
|
| 02/21/29 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 3,350 |
|
|
| — |
|
|
|
| 12.9000 |
|
| 02/28/30 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 21,357 |
|
|
| 3,643 |
| (1) |
|
| 7.2000 |
|
| 07/13/30 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 42,712 |
|
|
| 17,588 |
| (1) |
|
| 13.1300 |
|
| 02/09/31 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 124,847 |
|
|
| 114,853 |
| (1) (10) |
|
| 11.4700 |
|
| 11/01/31 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 38,958 |
|
|
| 46,042 |
| (1) |
|
| 10.1300 |
|
| 02/09/32 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
| 36,731 |
|
|
| 28,569 |
| (1) |
|
| 9.4500 |
|
| 09/06/32 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| — |
|
|
| 124,755 |
| (1) |
|
| 3.2600 |
|
| 01/05/33 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| — |
|
|
| 100,000 |
| (1) |
|
| 9.1100 |
|
| 07/10/33 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 131,347 |
| (5) |
|
| 3,035,429 |
|
|
|
|
|
| |||
Nancy Lurker |
|
| 85,000 |
|
|
| — |
| (11) |
|
| 36.3000 |
|
| 09/15/26 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
| 24,000 |
|
|
| — |
| (11) |
|
| 17.7000 |
|
| 06/27/27 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 54,000 |
|
|
| — |
| (11) |
|
| 20.4000 |
|
| 06/14/28 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 93,000 |
|
|
| — |
| (11) |
|
| 26.5000 |
|
| 02/21/29 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 71,684 |
|
|
| 3,116 |
| (2) (11) |
|
| 12.9000 |
|
| 02/28/30 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 151,370 |
|
|
| 62,330 |
| (2) (11) |
|
| 13.1300 |
|
| 02/09/31 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
| 110,000 |
|
|
| 130,000 |
| (2) (11) |
|
| 10.1300 |
|
| 02/09/32 |
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
| — |
|
|
| 450,800 |
| (2) |
|
| 3.2600 |
|
| 01/05/33 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| — |
|
|
| 66,666 |
| (2) |
|
| 9.1100 |
|
| 07/10/33 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
| 316,268 |
| (6) |
|
| 7,308,953 |
|
|
|
|
|
| ||||
George Elston |
|
| 74,500 |
|
|
| — |
|
|
|
| 14.2000 |
|
| 11/14/29 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| 10,579 |
|
|
| 458 |
| (3) |
|
| 12.9000 |
|
| 02/28/30 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| 42,712 |
|
|
| 17,588 |
| (3) |
|
| 13.1300 |
|
| 02/09/31 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| 32,083 |
|
|
| 37,917 |
| (3) |
|
| 10.1300 |
|
| 02/09/32 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| — |
|
|
| 91,655 |
| (3) |
|
| 3.2600 |
|
| 01/05/33 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| — |
|
|
| 45,000 |
| (3) |
|
| 5.9300 |
|
| 05/24/33 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| — |
|
|
| 30,000 |
| (3) |
|
| 8.2300 |
|
| 10/15/33 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 84,989 |
| (7) |
|
| 1,964,096 |
|
|
|
|
|
| |||
Dario Paggiarino |
|
| 23,000 |
|
|
| — |
|
|
|
| 39.3000 |
|
| 08/01/26 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| 6,000 |
|
|
| — |
|
|
|
| 17.7000 |
|
| 06/27/27 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| 17,050 |
|
|
| — |
|
|
|
| 20.4000 |
|
| 06/14/28 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| 37,000 |
|
|
| — |
|
|
|
| 26.5000 |
|
| 02/21/29 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| 23,599 |
|
|
| 1,026 |
| (4) |
|
| 12.9000 |
|
| 02/28/30 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| 42,712 |
|
|
| 17,588 |
| (4) |
|
| 13.1300 |
|
| 02/09/31 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| — |
|
|
| 37,917 |
| (4) |
|
| 10.1300 |
|
| 02/09/32 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
| — |
|
|
| 91,655 |
| (4) |
|
| 3.2600 |
|
| 01/05/33 |
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 62,489 |
| (8) |
|
| 1,444,121 |
|
|
|
|
|
|
29
Additional Narrative Disclosure
Stock Ownership Guidelines
We have adopted stock ownership guidelines for our executive officers. These guidelines were established to further align the interests of our executive officers with those of our stockholders and to promote our commitment to sound corporate governance practices. During 2022,In 2021, upon the guidance of Radford,Aon, the ownership guidelines for our executive officers were updated and are listed below:
Multiple of Base Salary | ||||
Chief Executive Officer |
| 3x | ||
Each Other Executive Officer covered by the Guidelines |
| 1x |
Owned shares as well as unvested time-based restricted shares are counted towards meeting the guidelines.
All executive officers have five years from the date of their appointment as a Section 16 officer (or the date on which the Compensation Committee adopts new guidelines) to meet these guidelines, and their stock ownership is reviewed annually by the Compensation Committee. For Ms. Lurker the compliance deadline is August 1, 2026, for Dr. Duker the compliance deadline is November 1, 2026 and for Ms. Lurker and Mr. PineElston the compliance deadline is January 10, 2027.August 1, 2026. As of April 23, 2024, all of the listed Named Executive Officers were in compliance with these guidelines.
Clawback Policy
30
We have adopted a compensation recoupment, or clawback, policy, that permitswhich we adopted in October 2023 to comply with Nasdaq listing standards implementing Exchange Act Rule 10D-1. The clawback policy includes mandatory recoupment of excess incentive-based compensation received by a covered executive (including the Company to recover, from any currentNamed Executive Officers) on or former executive officer, including any named executive officer, whose fraud or intentional misconduct contributes toafter October 2, 2023 in the circumstances requiringevent of a restatement of the Company to prepare an accounting restatementCompany’s financial statements due to material non-compliance of the Company with any financial reporting requirement under U.S. federal securities laws, up to 100% of any incentive-based compensation receivedas required by such officer from the Company during the one-year period preceding the date on which the Company is required to prepare such accounting restatement. Our Board of Directors plans to amend theExchange Act Rule 10D-1. The clawback policy once Nasdaq adopts listing standards requiring listed issuers to adopt and comply withreplaced our former clawback policies and to provide disclosure about their policies, consistent with a final SEC rule adoptedpolicy in November 2022 to implement Section 954 of the Dodd-Frank Act.its entirety.
Termination-Based Compensation
Nancy Lurker
Effective as of January 3, 2023, the role of President of the Company transitioned from Nancy Lurker to Dr. Duker. Ms. Lurker remains Chief Executive Officer of the Company. On January 3, 2023, the Company and Ms. Lurker entered into an amendment (the Lurker Employment Agreement Amendment) to her employment agreement, initially effective as of September 15, 2016 (the Lurker Employment Agreement).
If Ms. Lurker’s employment is terminated by the Company without Cause or by Ms. Lurker for Good Cause (as such terms are defined in the Lurker Employment Agreement), Ms. Lurker will be entitled to (a) her base salary for the period of 18 months from the date of termination; (b) 100% of her target bonus for the calendar year in which her employment terminates, pro-rated through the date of termination; (c) 150% of her target bonus, in each case of (a), (b) and (c), payable in equal installments during the period of base salary continuation payable in clause (a); and (d) reimbursements equal to the portion of the monthly health premiums paid by the Company on Ms. Lurker’s behalf and that of her eligible dependents immediately preceding the date that Ms. Lurker’s employment terminates until the earlier of (A) the last day of the period of base salary continuation under clause (a) and (B) the date that Ms. Lurker and her eligible dependents become ineligible for COBRA coverage. In addition, any unvested options to purchase common stock of the Company held by Ms. Lurker as of immediately prior to her termination of employment that would have vested as of the eighteen (18) month anniversary of the date of her termination of employment had she remained in continuous employment with the Company or any subsidiary through such eighteen (18) month anniversary will vest upon Ms. Lurker’s termination of employment and shall remain exercisable until the earlier of three (3) months following the date of Ms. Lurker’s termination of employment and the last day of the option term.
In the event Ms. Lurker’s employment is terminated by the Company without Cause or by Ms. Lurker for Good Cause within 60 days prior to, or within 18 months following a "Change of Control" (as such term is defined in the Lurker Employment Agreement), the Company will pay Ms. Lurker (i) her base salary for 24 months from the date of termination, payable in a lump sum; (ii) 100% of her target bonus for the calendar year in which her employment terminates, pro-rated through the date of termination payable in a lump sum; (iii) 200% of her target bonus payable in a lump sum; and (iv) reimbursements equal to the portion of the monthly health
premiums paid by the Company on Ms. Lurker’s behalf and that of her eligible dependents immediately preceding the date that Ms. Lurker’s employment terminates until the earlier of (A) the end of the twenty-four (24) month period immediately following the date of termination and (B) the date that Ms. Lurker and her eligible dependents become ineligible for COBRA coverage. In addition, all of Ms. Lurker’s then-outstanding equity awards will immediately accelerate and vest in full upon such termination of employment (or, if later, upon the occurrence of the Change of Control) and any such equity awards that are subject to exercise shall remain exercisable until the earlier of the first anniversary of the date of Ms. Lurker’s termination (or three (3) months following the date of her employment termination in the case of any incentive stock options) and the last day of the option term.
In addition to the payments set forth in the preceding paragraphs, upon the termination of Ms. Lurker’s employment for any reason, Ms. Lurker will be entitled to receive any earned or accrued amounts and vested benefits that remain unpaid as of the date of her termination of employment.
Ms. Lurker’s right to receive the severance payments and benefits described above under her employment agreement is conditioned upon her execution and non-revocation of a separation agreement containing a general release of claims. Ms. Lurker’s employment agreement contains certain restrictive covenants, including non-disclosure of confidential information, assignment of rights to intellectual property, a non-competition covenant that runs for 12 months following her termination of employment for any reason, a non-solicitation covenant with respect to certain of our customers, vendors, suppliers and business partners that runs for 12 months following her termination of employment for any reason and a non-solicitation covenant with respect to our employees and independent contractors that runs for 12 months following her termination of employment.
Jay Duker
Effective January 3,July 10, 2023, the Board of Directors of the Company appointed Jay S.Dr. Duker, M.D., as the Company's President and Chief Operating Officer.Executive Officer, effective as of July 10, 2023. In connection with Dr. Duker’s appointment to President and Chief Executive Officer, the Company and Dr. Duker entered into an amendment (the Duker Employment Agreement Amendment) to histhat certain Amended and Restated Employment Agreement, initially effective as of November 1, 2021, (theas amended by that certain First Amendment to Employment Letter Agreement, effective as of January 3, 2023, by and between the Company and Dr. Duker (as amended, the Duker Employment Agreement).
If Dr. Duker’s employment is terminated by the Company without Cause or by Dr. Duker for Good Cause (as such terms are defined in the Duker Employment Agreement), Dr. Duker will be entitled to (a) his base salary for the period of 12 months from the date of termination; (b) 100% of his target bonus for the calendar year in which his employment terminates, pro-rated through the date of termination; (c) 100% of his target bonus, in each case of (a), (b) and (c), payable in equal installments during the period of base salary continuation payable in clause (a); and (d) reimbursements equal to the portion of the monthly health premiums paid by the Company on Dr. Duker’s behalf and that of his eligible dependents immediately preceding the date that Dr. Duker’s employment terminates until the earlier of (i) the last day of the period of base salary continuation under clause (a) and (ii) the date that Dr. Duker and his eligible dependents become ineligible for COBRA coverage. In addition, any unvested equity awards held by Dr. Duker as of immediately prior to his termination of employment that would have vested as of the first anniversary of the date of his termination of employment had he remained in continuous employment with the Company or any subsidiary through such first anniversary will vest upon Dr. Duker’s termination of employment and any such equity awards that are subject to exercise shall remain exercisable until the earlier of three (3) months following the date of Dr. Duker’s termination of employment and the last day of the option term.
In the event Dr. Duker’s employment is terminated by the Company without Cause or by Dr. Duker for Good Cause within 60 days prior to, or within 18 months following a "Change of Control" (as such term is defined in the Duker Employment Agreement), the Company will pay Dr. Duker (i) his base salary for 18 months from the date of termination, payable in a lump sum; (ii) 100% of his target bonus for the calendar year in which his employment terminates, pro-rated through the date of termination payable in a lump sum; (iii) 150% of his target bonus payable in a lump sum; and (iv) reimbursements equal to the portion of the monthly health premiums paid by the Company on Dr. Duker’s behalf and that of his eligible dependents immediately preceding the date that Dr. Duker’s employment terminates until the earlier of (A) the last day of the period of base salary continuation under clause (i) and (B) the date that Dr. Duker and his eligible dependents become ineligible for COBRA coverage. In addition, all of Dr. Duker’s then-outstanding equity awards will immediately accelerate and vest in full upon such termination of employment (or, if later, upon the occurrence of the Change of Control) and any such equity awards that are subject to exercise shall remain exercisable until the earlier of the first anniversary of the date of Dr. Duker’s termination (or three (3) months following the date of his employment termination in the case of any incentive stock options) and the last day of the option term.
In addition to the payments set forth in the preceding paragraphs, upon the termination of Dr. Duker’s employment for any reason, Dr. Duker will be entitled to receive any earned or accrued amounts and vested benefits that remain unpaid as of the date of his termination of employment.
Dr. Duker’s right to receive the severance payments and benefits described above under his employment agreement is conditioned upon his execution and non-revocation of a separation agreement containing a general release of claims. Dr. Duker’s employment agreement contains certain restrictive covenants, including non-disclosure of confidential information, assignment of rights to intellectual property, a non-competition covenant that runs for 12 months following his termination of employment for any reason, a non-solicitation covenant with respect to certain of our customers, vendors, suppliers, and business partners that runs for 12 months following his termination of employment for any reason, and a non-solicitation covenant with respect to our employees and independent contractors that runs for 12 months following his termination of employment.
Michael PineNancy Lurker
On
Effective as of July 10, 2023, Ms. Lurker transitioned from her role as Chief Executive Officer of the Company to Executive Vice Chair of Board of Directors. Ms. Lurker continues to serve as a member of the Board.
31
In connection with Ms. Lurker’s transition, the Company and Ms. Lurker entered into an amendment (the Lurker Amendment to that certain Employment Letter Agreement, dated September 15, 2016, as amended by that certain First Amendment to Employment Letter Agreement, effective as of January 3, 2023, by and between the Company entered into an amended and restated employment agreement with Michael Pine, the Company’s Senior Vice President and Chief Commercial OfficerMs. Lurker (as amended, the Amended & Restated PineLurker Employment Agreement). The Lurker Amendment provides that Ms. Lurker will serve as Executive Vice Chair for one year from the Lurker Transition Date (the Initial Term), subject to an extension of up to six months upon the expiration of the Initial Term by the Board at its sole discretion (if exercised by the Board, the Extension Term and together with the Initial Term, the Term). Under the Lurker Amendment, expiration of the Term will not constitute a termination of employment by the Company without Cause (as defined in the Lurker Employment Agreement) or constitute grounds for Ms. Lurker to terminate her employment for Good Cause (as defined in the Lurker Employment Agreement).
If Ms. Lurker’s employment is terminated by the Company without Cause or by Ms. Lurker for Good Cause (as such terms are defined in the Lurker Employment Agreement), Ms. Lurker will be entitled to (a) her base salary for the period of 18 months from the date of termination; (b) 100% of her target bonus for the calendar year in which her employment terminates, pro-rated through the date of termination; (c) 150% of her target bonus, in each case of (a), (b) and (c), payable in equal installments during the period of base salary continuation payable in clause (a); and (d) reimbursements equal to the portion of the monthly health premiums paid by the Company on Ms. Lurker’s behalf and that of her eligible dependents immediately preceding the date that Ms. Lurker’s employment terminates until the earlier of (A) the last day of the period of base salary continuation under clause (a) and (B) the date that Ms. Lurker and her eligible dependents become ineligible for COBRA coverage. In addition, any unvested options to purchase common stock of the Company held by Ms. Lurker as of immediately prior to her termination of employment that would have vested as of the eighteen (18) month anniversary of the date of her termination of employment had she remained in continuous employment with the Company or any subsidiary through such eighteen (18) month anniversary will vest upon Ms. Lurker’s termination of employment and shall remain exercisable until the earlier of three (3) months following the date of Ms. Lurker’s termination of employment and the last day of the option term.
In the event Ms. Lurker’s employment is terminated by the Company without Cause or by Ms. Lurker for Good Cause within 60 days prior to, or within 18 months following a "Change of Control" (as such term is defined in the Lurker Employment Agreement), the Company will pay Ms. Lurker (i) her base salary for 24 months from the date of termination, payable in a lump sum; (ii) 100% of her target bonus for the calendar year in which her employment terminates, pro-rated through the date of termination payable in a lump sum; (iii) 200% of her target bonus payable in a lump sum; and (iv) reimbursements equal to the portion of the monthly health premiums paid by the Company on Ms. Lurker’s behalf and that of her eligible dependents immediately preceding the date that Ms. Lurker’s employment terminates until the earlier of (A) the end of the twenty-four (24) month period immediately following the date of termination and (B) the date that Ms. Lurker and her eligible dependents become ineligible for COBRA coverage. In addition, all of Ms. Lurker’s then-outstanding equity awards will immediately accelerate and vest in full upon such termination of employment (or, if later, upon the occurrence of the Change of Control) and any such equity awards that are subject to exercise shall remain exercisable until the earlier of the first anniversary of the date of Ms. Lurker’s termination (or three (3) months following the date of her employment termination in the case of any incentive stock options) and the last day of the option term.
In addition to the payments set forth in the preceding paragraphs, upon the termination of Ms. Lurker’s employment for any reason, Ms. Lurker will be entitled to receive any earned or accrued amounts and vested benefits that remain unpaid as of the date of her termination of employment.
Ms. Lurker’s right to receive the severance payments and benefits described above under her employment agreement is conditioned upon her execution and non-revocation of a separation agreement containing a general release of claims. Ms. Lurker’s employment agreement contains certain restrictive covenants, including non-disclosure of confidential information, assignment of rights to intellectual property, a non-competition covenant that runs for 12 months following her termination of employment for any reason, a non-solicitation covenant with respect to certain of our customers, vendors, suppliers, and business partners that runs for 12 months following her termination of employment for any reason, and a non-solicitation covenant with respect to our employees and independent contractors that runs for 12 months following her termination of employment.
George Elston
If Mr. Pine’sElston’s employment is terminated by the Company without Cause or by Mr. PineElston for Good Cause (as such terms are defined in the Amended & Restated PineA&R Elston Employment Agreement), Mr. PineElston will be entitled to (a) his base salary for the period of 12 months from the date of termination; (b) 100% of his target bonus for the calendar year in which his employment terminates, pro-rated through the date of termination; (c) 100% of his target bonus, in each case of (a), (b), and (c), payable in equal installments during the period of base salary continuation payable in clause (a); and (d) reimbursements equal to the portion of the monthly health premiums paid by the Company on Mr. Pine'sElston’s behalf and that of his eligible dependents immediately preceding the date that Mr. Pine'sElston’s employment terminates until the earlier of (i) the last day of the period of base salary continuation under clause (a) and (ii) the date that Mr. Pine Elston
32
and his eligible dependents become ineligible for COBRA coverage. In addition, any unvested equity awards held by Mr. PineElston as of immediately prior to his termination of employment that would have vested as of the first anniversary of the date of his termination of employment had he remained in continuous employment with the Company or any subsidiary through such first anniversary will vest upon Mr. Pine'sElston’s termination of employment and any such equity awards that are subject to exercise shall remain exercisable until the earlier of three (3) months following the date of Mr. Pine'sElston’s termination of employment and the last day of the option term.
IfIn the event Mr. Pine'sElston’s employment is terminated by the Company without Cause or by Mr. PineElston for Good Cause within 60 days prior to, or within 18 months following a "Change of Control" (as such term is defined in the Amended & Restated PineElston Employment Agreement), the Company will pay Mr. PineElston (i) his base salary for 18 months from the date of termination, payable in a lump sum; (ii) 100% of his target bonus for the calendar year in which his employment terminates, pro-rated through the date of termination payable in a lump sum; (iii) 150% of his target bonus payable in a lump sum; and (iv) reimbursements equal to the portion of the monthly health premiums paid by the Company on Mr. Pine'sElston’s behalf and that of his eligible dependents immediately preceding the date that Mr. Pine'sElston’s employment terminates until the earlier of (A) the end of the eighteen (18) month period immediately following the date of termination and (B) the date that Mr. PineElston and his eligible dependents become ineligible for COBRA coverage. In addition, all of Mr. Pine'sElston’s then-outstanding equity awards will immediately accelerate and vest in full upon such termination of employment (or, if later, upon the occurrence of the Change of Control) and any such equity awards that are subject to exercise shall remain exercisable until the earlier of three (3) months following the date of his employment termination and the last day of the option term.
In addition to the payments set forth in the preceding paragraphs, upon the termination of Mr. Pine'sElston's employment for any reason, Mr. PineElston will be entitled to receive any earned or accrued amounts and vested benefits that remain unpaid as of the date of his termination of employment.
Mr. Pine’sElston’s right to receive the severance payments and benefits described above under his employment agreement is conditioned upon his execution and non-revocation of a separation agreement containing a general release of claims. Mr. Pine'sElston's employment agreement contains certain restrictive covenants, including non-disclosure of confidential information, assignment of rights to intellectual property, a non-competition covenant that runs for 12 months following his termination of employment for any reason, a non-solicitation covenant with respect to certain of our customers, vendors, suppliers, and business partners that runs for 12 months following his termination of employment for any reason, and a non-solicitation covenant with respect to our employees and independent contractors that runs for 12 months following his termination of employment.
Dario Paggiarino
Dr. Paggiarino's employment with the Company terminated involuntarily effective March 29, 2024 (Separation Date). Pursuant to the Severance and General Release Agreement entered into between Dr. Paggiarino and the Company, Dr. Paggiarino received severance pay in the amount of $807,950, which included (a) his base salary for the period of 12 months from the Separation Date ($517,088), plus (b) 100% of his target bonus for the 2024 calendar year ($232,689.60), plus (c) 100% of his target bonus for the 2024 calendar year, pro-rated through the Separation Date ($58,172.40). The severance payments will be payable in equal twice-monthly installments during the 12-month period of base salary continuation.
The vesting of Dr. Paggiarino’s unvested stock options (the Accelerated Stock Options) and unvested restricted stock units (the Accelerated RSUs) accelerated by two years as of the Separation Date, and such Accelerated Stock Options and Accelerated RSUs were deemed fully vested on the Separation Date. Further, Dr. Paggiarino's previously vested stock options as of the Separation Date and the Accelerated Stock Options will remain outstanding and exercisable until the date that is 12 months following the Separation Date. Dr. Paggiarino held 211,978 options exercisable and 50,404 vested RSUs, including Accelerated Stock Options and Accelerated RSUs, as of the Separation Date
Dr. Paggiarino is entitled to receive reimbursements equal to the portion of the monthly health premiums paid by the Company on Dr. Paggiarino’s behalf and that of his eligible dependents immediately preceding the date of termination until the earlier of (i) the last day of the period of base salary continuation and (ii) the date that Dr. Paggiarino and his eligible dependents become ineligible for COBRA coverage.
Dr. Paggiarino’s right to receive the severance payments and benefits described above were conditioned upon his agreement to a general release of claims. Dr. Paggiarino's employment agreement contains certain restrictive covenants, including non-disclosure of confidential information, assignment of rights to intellectual property, a non-competition covenant that runs for 12 months following his termination of employment, a non-solicitation covenant with respect to certain of our customers, vendors, suppliers, and business partners that runs for 12 months following his termination of employment, and a non-solicitation covenant with respect to our employees and independent contractors that runs for 12 months following his termination of employment.
33
DIRECTOR COMPENSATION
Compensation Summary
The following table and footnotes provide information regarding the compensation paid to our non-executive directors for the year ended December 31, 2022:2023:
Name |
| Fees Earned |
|
| Option |
|
| Stock |
|
| All Other |
|
| Total ($) |
|
| Fees Earned |
|
| Option |
|
| Stock |
|
| All Other |
|
| Total ($) |
| ||||||||||
Göran Ando |
|
| 114,250 |
|
|
| 79,653 |
|
|
| 32,922 |
|
|
| — |
|
|
| 226,825 |
|
|
| 117,000 |
|
|
| 97,784 |
|
|
| — |
|
|
| — |
|
|
| 214,784 |
|
Ron Eastman(3) |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
| ||||||||||||||||||||
John Landis |
|
| 63,750 |
|
|
| 73,015 |
|
|
| 30,390 |
|
|
| — |
|
|
| 167,155 |
| ||||||||||||||||||||
John Landis(3) |
|
| 67,500 |
|
|
| 94,171 |
|
|
| — |
|
|
| — |
|
|
| 161,671 |
| ||||||||||||||||||||
David Guyer |
|
| 80,000 |
|
|
| 73,015 |
|
|
| 30,390 |
|
|
| — |
|
|
| 183,405 |
|
|
| 86,500 |
|
|
| 94,171 |
|
|
| — |
|
|
| — |
|
|
| 180,671 |
|
Wendy DiCicco |
|
| 73,750 |
|
|
| 73,015 |
|
|
| 30,390 |
|
|
| — |
|
|
| 177,155 |
|
|
| 77,500 |
|
|
| 94,171 |
|
|
| — |
|
|
| — |
|
|
| 171,671 |
|
Ye Liu(4) |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Anthony P. Adamis |
|
| 27,404 |
|
|
| 113,591 |
|
|
| 45,240 |
|
|
| — |
|
|
| 186,235 |
|
|
| 52,500 |
|
|
| 94,171 |
|
|
| — |
|
|
| — |
|
|
| 146,671 |
|
Karen Zaderej |
|
| 27,500 |
|
|
| 123,547 |
|
|
| 49,320 |
|
|
| — |
|
|
| 200,367 |
|
|
| 55,000 |
|
|
| 94,171 |
|
|
| — |
|
|
| — |
|
|
| 149,171 |
|
Stuart Duty |
|
| 9,932 |
|
|
| 371,164 |
|
|
| — |
|
|
| — |
|
|
| 381,096 |
|
Name |
| Outstanding |
|
| Outstanding |
|
| Outstanding |
|
| Outstanding |
| ||||
Göran Ando |
|
| 42,350 |
|
|
| 3,250 |
|
|
| 82,950 |
|
|
| — |
|
Ron Eastman |
|
| — |
|
|
| — |
| ||||||||
John Landis |
|
| 37,350 |
|
|
| 3,000 |
|
|
| 76,450 |
|
|
| — |
|
David Guyer |
|
| 33,350 |
|
|
| 3,000 |
|
|
| 72,450 |
|
|
| — |
|
Wendy DiCicco |
|
| 33,350 |
|
|
| 3,000 |
|
|
| 72,450 |
|
|
| — |
|
Ye Liu |
|
| — |
|
|
| — |
|
|
| — |
|
|
| — |
|
Anthony P. Adamis |
|
| 22,000 |
|
|
| 6,000 |
|
|
| 61,100 |
|
|
| 4,000 |
|
Karen Zaderej |
|
| 22,000 |
|
|
| 6,000 |
|
|
| 61,100 |
|
|
| 4,000 |
|
Stuart Duty |
|
| 60,000 |
|
|
| — |
|
Elements of Non-Executive Director Compensation
The rates of compensation to our non-executive directors in effect for the year ended December 31, 2022,2023, and continuing until otherwise modified in the future, were as follows:
34
On (1) December 14, 2022 and (2) February 22,13, 2023 , the Compensation Committee approved the following annual equity awards consisting of stock options as described above. Each of these equity awards are subject to the approval of Annual Meeting Proposal No. 2, as discussed further below, to approve our 2023 Long-Term Incentive Plan.
Name |
| Option |
| Option |
| ||
Göran Ando |
|
| 27,100 |
|
| 13,500 |
|
John Landis |
|
| 26,100 |
|
| 13,000 |
|
David Guyer |
|
| 26,100 |
|
| 13,000 |
|
Wendy DiCicco |
|
| 26,100 |
|
| 13,000 |
|
Ye Liu |
|
| — |
|
| — |
|
Anthony P. Adamis |
|
| 26,100 |
|
| 13,000 |
|
Karen Zaderej |
|
| 26,100 |
|
| 13,000 |
|
Name | Option | Stock | |||||
Göran Ando | 23,598 | — | |||||
John Landis | 25,014 | — | |||||
David Guyer | 25,014 | — | |||||
Wendy DiCicco | 25,014 | — | |||||
Ye Liu | — | — | |||||
Anthony P. Adamis | 25,014 | — | |||||
Karen Zaderej | 25,014 | — | |||||
Stuart Duty | 25,014 | — |
Dr. Duker and Ms. Lurker receivesreceive no additional compensation for serving as a director. Mr. Liu does not receive compensation for serving as a director, although he is entitled to seek reimbursement for reasonable expenses incurred in connection with service on the Board and is entitled to the same benefits, including benefits under any director and officer indemnification or insurance policy maintained by us, as any other non-employee director of the Board.
As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K, we are providing the following disclosure regarding executive compensation for our principal executive officer (PEO) and Non-PEO NEOs and Company performance for the fiscal years listed below. The Compensation Committee did not consider the pay versus performance disclosure below in making its pay decisions for any of the years shown.
PAY VERSUS PERFORMANCE DISCLOSURE
Year |
| Summary Compensation Table Total for Nancy Lurker(1) |
| Compensation Actually Paid to Nancy Lurker(1),(2),(3) |
| Average Summary Compensation Table Total for Non-PEO NEOs(1) |
| Average Compensation Actually Paid to Non-PEO NEOs(1),(2),(3) |
| Value of Initial Fixed $100 Investment based on | Net Loss |
|
| Summary Compensation Table Total for First PEO |
| Compensation Actually Paid to First PEO |
| Summary Compensation Table Total for Second PEO(1) |
| Compensation Actually Paid to Second PEO |
| Average Summary Compensation Table Total for Non-PEO NEOs |
| Average Compensation Actually Paid to Non-PEO NEOs |
| Value of Initial Fixed $100 Investment based on | Net Loss |
| ||||||||||||
(a) |
| (b) |
| (c) |
| (d) |
| (e) |
| (f) | (g) |
|
| (b) |
| (c) |
| (b) |
| (c) |
| (d) |
| (e) |
| (f) | (g) |
| ||||||||||||
2023 |
|
| 3,737,385 |
| 23,226,384 |
| 2,915,146 |
| 12,936,773 |
| 1,539,141 |
| 6,445,530 |
| 351.22 |
| (70,795 | ) | ||||||||||||||||||||||
2022 |
|
| 3,445,218 |
| 330,205 |
| 1,838,840 |
| 116,687 |
| 53.19 |
| (102,254 | ) |
|
| 3,445,218 |
| 330,205 |
| — |
| — |
| 1,838,840 |
| 116,687 |
| 53.19 |
| (102,254 | ) | ||||||||
2021 |
|
| 3,623,368 |
| 4,121,046 |
| 2,075,237 |
| 2,242,435 |
| 186.02 |
| (58,417 | ) |
|
| 3,623,368 |
| 4,121,046 |
| — |
| — |
| 2,075,237 |
| 2,242,435 |
| 186.02 |
| (58,417 | ) |
2022 | 2021 |
Jay Duker | Jay Duker |
Michael Pine | George Elston |
— | Scott Jones |
2023 | 2022 | 2021 |
George Elston | Jay Duker | Jay Duker |
Dario Paggiarino | Michael Pine | George Elston |
— | — | Scott Jones |
35
Year |
| Summary Compensation Table Total for Nancy Lurker |
| Exclusion of Stock Awards and Option Awards for Nancy Lurker |
| Inclusion of Equity Values for Nancy Lurker (5) |
| Compensation Actually Paid to Nancy Lurker |
| ||||
2022 |
|
| 3,445,218 |
|
| (2,244,176 | ) |
| (870,837 | ) |
| 330,205 |
|
2021 |
|
| 3,623,368 |
|
| (2,513,523 | ) |
| 3,011,201 |
|
| 4,121,046 |
|
Year |
| Summary Compensation Table Total for First PEO |
| Exclusion of Stock Awards and Option Awards for First PEO |
| Inclusion of Equity Values for First PEO |
| Compensation Actually Paid to First PEO |
| ||||
2023 |
|
| 3,737,385 |
|
| (2,518,105 | ) |
| 22,007,104 |
|
| 23,226,384 |
|
2022 |
|
| 3,445,218 |
|
| (2,244,176 | ) |
| (870,837 | ) |
| 330,205 |
|
2021 |
|
| 3,623,368 |
|
| (2,513,523 | ) |
| 3,011,201 |
|
| 4,121,046 |
|
Year |
| Average Summary Compensation Table Total for Non-PEO NEOs |
| Average Exclusion of Stock Awards and Option Awards for Non-PEO NEOs |
| Average Inclusion of Equity Values for Non-PEO NEOs (5) |
| Average Compensation Actually Paid to Non-PEO NEOs |
| ||||
2022 |
|
| 1,838,840 |
|
| (1,032,163 | ) |
| (689,990 | ) |
| 116,687 |
|
2021 |
|
| 2,075,237 |
|
| (1,398,271 | ) |
| 1,565,469 |
|
| 2,242,435 |
|
Year |
| Summary Compensation Table Total for Second PEO |
| Exclusion of Stock Awards and Option Awards for Second PEO |
| Inclusion of Equity Values for Second PEO |
| Compensation Actually Paid to Second PEO |
| ||||
2023 |
|
| 2,915,146 |
|
| (1,620,652 | ) |
| 11,642,279 |
|
| 12,936,773 |
|
Year |
| Average Summary Compensation Table Total for Non-PEO NEOs |
| Average Exclusion of Stock Awards and Option Awards for Non-PEO NEOs |
| Average Inclusion of Equity Values for Non-PEO NEOs |
| Average Compensation Actually Paid to Non-PEO NEOs |
| ||||
2023 |
|
| 1,539,141 |
|
| (616,651 | ) |
| 5,523,040 |
|
| 6,445,530 |
|
2022 |
|
| 1,838,840 |
|
| (1,032,163 | ) |
| (689,990 | ) |
| 116,687 |
|
2021 |
|
| 2,075,237 |
|
| (1,398,271 | ) |
| 1,565,469 |
|
| 2,242,435 |
|
Year |
| Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Nancy Lurker |
| Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Nancy Lurker |
| Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Nancy Lurker | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Nancy Lurker |
| Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Nancy Lurker | Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included for Nancy Lurker | Total - Inclusion of Equity Values for Nancy Lurker |
|
| Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for First PEO |
| Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for First PEO |
| Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for First PEO | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for First PEO |
| Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for First PEO | Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included for First PEO | Total - Inclusion of Equity Values for First PEO |
| ||||||||
2023 |
|
| 17,026,387 |
| 4,670,046 |
| — |
| 310,671 |
| — |
| 22,007,104 |
| ||||||||||||||||||
2022 |
|
| 688,870 |
| (1,189,689 | ) | — |
| (370,018 | ) | — |
| (870,837 | ) |
|
| 688,870 |
| (1,189,689 | ) | — |
| (370,018 | ) | — |
| (870,837 | ) | ||||
2021 |
|
| 2,298,742 |
| 420,347 |
| — |
| 292,112 |
| — |
| 3,011,201 |
|
|
| 2,298,742 |
| 420,347 |
| — |
| 292,112 |
| — |
| 3,011,201 |
|
Year |
| Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Second PEO |
| Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Second PEO |
| Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Second PEO | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Second PEO |
| Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Second PEO | Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included for Second PEO | Total - Inclusion of Equity Values for Second PEO |
| ||||
2023 |
|
| 7,295,077 |
|
| 3,954,380 |
| — |
| 392,822 |
| — | — |
| 11,642,279 |
|
Year |
| Average Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Non-PEO NEOs |
| Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Non-PEO NEOs |
| Average Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Non-PEO NEOs | Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Non-PEO NEOs |
| Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non-PEO NEOs | Average Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included for Non-PEO NEOs | Total - Average Inclusion of Equity Values for Non-PEO NEOs |
| ||||
2022 |
|
| 283,177 |
|
| (691,721 | ) | — |
| (281,446 | ) | — | — |
| (689,990 | ) |
2021 |
|
| 1,395,818 |
|
| 126,432 |
| — |
| 43,219 |
| — | — |
| 1,565,469 |
|
36
Year |
| Average Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Non-PEO NEOs |
| Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Non-PEO NEOs |
| Average Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Non-PEO NEOs | Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Non-PEO NEOs |
| Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non-PEO NEOs | Average Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included for Non-PEO NEOs | Total - Average Inclusion of Equity Values for Non-PEO NEOs |
| ||||
2023 |
|
| 4,068,229 |
|
| 1,344,732 |
| — |
| 110,079 |
| — | — |
| 5,523,040 |
|
2022 |
|
| 283,177 |
|
| (691,721 | ) | — |
| (281,446 | ) | — | — |
| (689,990 | ) |
2021 |
|
| 1,395,818 |
|
| 126,432 |
| — |
| 43,219 |
| — | — |
| 1,565,469 |
|
Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Company Total Shareholder Return (TSR)
The following chart sets forth the relationship between Compensation Actually Paid to our First PEO and Second PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and the Company’s cumulative TSR over the twothree most recently completed fiscal years.
37
Description of Relationship Between PEOPEOs and Non-PEO NEO Compensation Actually Paid and Net Loss
The following chart sets forth the relationship between Compensation Actually Paid to our First PEO and Second PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Net Loss during the twothree most recently completed fiscal years.
38
PROPOSAL 1
ELECTION OF EIGHTNINE DIRECTORS
The Board currently consists of eightten directors, Göran Ando, Jay Duker, Nancy Lurker, John Landis, Ye Liu, David Guyer, Wendy DiCicco, Ye Liu, Anthony Adamis, Karen Zaderej, and Karen Zaderej.Stuart Duty. Mr. Liu will not stand for re-election to the Board but will serve as a director until the expiration of his term at the Annual Meeting. At the recommendation of the Governance and Nominating Committee, the Board has re-nominated each of our other current directors for election at the Annual Meeting, effective as of the conclusion of the Annual Meeting. Each nominee, if elected, will hold office until our 20242025 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until he or she sooner dies, resigns, or is removed. Except as disclosed below, the proposed nominees are not being nominated pursuant to any arrangement or understanding with any person. We do not anticipate that any nominee will become unavailable to serve.
Biographical information and the attributes, skills, and experience of each nominee that led our Governance and Nominating Committee and Board to determine that such nominee should serve as a director are discussed in the “Directors and Executive Officers” section of this proxy statement.
Voting Standard
A plurality of the votes of the shares present personally or represented by proxy at the Annual Meeting is required to elect director nominees, and as such, the nine nominees who receive the greatest number of votes cast by stockholders entitled to vote on the matter will be elected. Broker non-votes and abstentions will have no effect on the outcome of this proposal.
Board Recommendation
THE BOARD RECOMMENDS THAT YOU VOTE FOR ALL ON PROPOSAL NO. 1 TO ELECT GÖRAN ANDO, JAY DUKER, NANCY LURKER, JOHN LANDIS, DAVID GUYER, WENDY DICICCO, YE LIU, ANTHONY ADAMIS, AND KAREN ZADEREJ, AND STUART DUTY TO THE BOARD.
39
PROPOSAL 2
APPROVAL OF AMENDMENT TO 2023 LONG-TERM INCENTIVE PLAN
On April 19, 2023 (Date of Adoption), our2024, the Board unanimously approved, subject to stockholder approval, an amendment (the 2023 Plan Amendment) to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan (2023(the 2023 Plan). We are asking our stockholders to approve the 2023 Plan Amendment approved by ourthe Board. If approved by stockholders, the 2023 Plan Amendment would replace(i) increase the 2016 Long-Term Incentive Plan (2016 Plan). The number of shares of our common stock that may be issued under the 2023 Plan will beby 4,000,000 shares, (the Share Increase) and (ii) increase the individual non-employee director compensation limit contained therein to $850,000 for ongoing directors and $1,100,000 for new directors in any calendar year. The amendment would also increase the ISO limit from 3,500,000 plus up to 159,000 remaining shares that remain available for grant under7,500,000 to align with the 2016 Plan, as of the Date of Adoption (less any shares underlying equity awards granted between the Date of Adoption and stockholder approval of the plan), plus any shares that would otherwise have become available for grant under the 2008 Plan or the 2016 Plan after the Date of Adoption as a result of the termination or forfeiture of awards under such plans. If the 2023 Plan is approved, no further awards will be made under the 2016 Plan or the 2008 Plan.Share Increase.
Background
We believe our
Our future success depends, in large part, upon our ability to maintain a competitive position in attracting, retaining, and motivating persons who are expected to make important contributions to our companythe Company by providing such persons with equity ownership opportunities and performance-based incentives. The life sciences industry in the Cambridge and Boston, Massachusetts market remainsis highly competitive, and our results are largely attributable to the talents, expertise, efforts, and dedication of our employees. Our compensation program, including the granting of equity compensation, is the primary means by which we attract and recruit new employees and directors, as well as retain our most experienced and skilled workforce.employees and directors.
Equity compensation is also fundamental to our compensation philosophy and core objectives of paying for performance and aligning the interests of employees and directors with those of stockholders. A significant portion of our employees' and directors' compensation is provided in the form of equity. We believe that equity awards, and the potential they hold for appreciation through an increase in our stock price, support our pay-for-performance philosophy, provide further incentive to our employees and directors to focus on creating long-term stockholder value and create an ownership culture that links employees' and directors' interests with those of our stockholders and our long-term results, performance, and financial condition.
In this labor market, we are often competing for highly-skilledhighly skilled and sought-after talent with many companies that have evergreen provisions in their equity incentive plans which provide for annual additions of new shares eligible for grant to current and prospective future employees.employees and directors. We do not have an evergreen provision in our equity plan that provides for annual refreshes of new shares to grant and, as such, we are required to request stockholders to approve a total share poolShare Increase that will sustain the Company’s equity incentive program for the next several years, and this request is intended to do so. We expect this share request,Share Increase, if approved, shouldto sustain the Company’s equity program for the next 1-2 years.
Additionally,
As of April 23, 2024, we had 6,441,982 shares of our common stock issuable upon the exercise of stock options outstanding under the 2023 Plan as well as 1,020,064 inducement options at a total weighted-average exercise price of $12.71, 1,402,385 shares of our common stock underlying outstanding restricted stock units under the 2023 Plan, and approximately 352,000 shares of our common stock available for the grant of future equity awards under the 2023 Plan.
We have carefully modeled our projected future share usage and needs for current employees and expected new hires to determine the appropriate share requestShare Increase amount. We have then studied the effect this share requestShare Increase and its approval would have on the total overhang of our equity program. We have thoughtfully compared these results to publicly disclosed share usage data from a set of biopharmaceutical companies that are comparable to us in terms of revenue, market value, stage of development, and headcount (peer companies or peer group). Our total overhang (shares outstanding + shares available), post this new plan approval would be reasonably positioned between the median and 75th percentile of our peer companies.
We believe the above positioning demonstrates the reasonableness of this share request and that it should be supported to allow the Company to compete successfully and create value for stockholders.
As of April 23, 2024, the DateCompany’s equity overhang, represented by (a) the sum of Adoption, there were noall outstanding share options and other awards, plus the number of shares available for the grant ofissuance pursuant to future equity awards under the 20082023 Plan, as a percentage of (b) the number of shares of common stock outstanding as of April 23, 2024 was approximately 18%. If the amendment to the 2023 Plan is approved by our stockholders and all shares utilized, our equity overhang would be approximately 25%.
Additionally, under the 2023 Plan, the aggregate value of all compensation granted or paid to any non-employee director with any respect to any calendar year, including all awards granted under the 2023 Plan and approximately 159,000 shares availableany other fees or compensation paid to such director outside of the 2023 Plan for services as director, may not exceed $750,000 in the grantdirector's initial year and $500,000 in subsequent years. If approved by stockholders, the 2023 Plan Amendment would increase the individual non-employee director compensation limit contained therein to $850,000 for ongoing directors and $1,100,000 for new directors in any calendar year to remain consistent and competitive the with limits of future equity awards undersimilar companies in the 2016 Plan. life sciences industry in the Cambridge and Boston, Massachusetts market.
Upon the recommendation of the Compensation Committee, the Board of Directors has approved, subject to stockholder approval, the 2023 Plan Amendment to increase the number of shares authorized for issuance under the 2023 Plan there will be an authorized 3,500,000by 4,000,000 shares availableand increase the individual non-employee director compensation limit contained therein to $850,000 for issuance, plus up to 159,000 remaining shares that remain availableongoing directors and $1,100,000 for grant under the2016 Plan as of the Date of Adoption (lessnew directors in any shares underlying equity awards granted between the Date of Adoption andstockholder approval of the plan), plus any shares that would otherwise have become available for grant under the 2008 Plan or the2016 Plan after the Date of Adoption as a result of the termination or forfeiture of awards under such plans.calendar year. The Board believes that equity awards providecompensation provides an important incentive for our employees, including our
40
executive officers, other key employees and our directors, to remain with the Company, to motivate them to help achieve our corporate objectives, and to align their interests with those of our stockholders. The Board voted to approveamendment would also increase the 2023 Plan to ensure we continue to provide appropriate equity incentives.incentive stock option limit by 4,000,000 shares.
On April 21, 2023,23, 2024, the closing price of our common stock on the Nasdaq Global Market was $9.00$17.57 per share.
Key Features of the 2023 Plan (as proposed to be amended by the 2023 Plan Amendment)
The 2023 Plan reflects a broad range of compensation and governance best practices, including the following:
Summary of the Material Terms of the 2023 Plan
The following summary describes the material terms of the 2023 Plan and provides a general description of the U.S. federal income tax consequences applicable to certain transactions involving awards under the 2023 Plan. The following description of certain features of the 2023 Plan is qualified in its entirety by reference to the full text of to the 2023 Plan, as proposed to be amended, attached to this Proxy Statement as “Annex A.”
Plan Administration. The 2023 Plan will beis administered by the Compensation Committee, which has the authority to, among other things, interpret the 2023 Plan, determine eligibility for, grant and determine, modify or waive the terms and conditions of awards under the 2023 Plan, and to do all things necessary or appropriate to carry out the purposes of the 2023 Plan. As administrator of the 2023 Plan, the Compensation Committee may amend the 2023 Plan at any time, with any such amendment to be conditioned upon stockholder approval only to the extent, if any, approval is required by law or applicable stock exchange requirements, as determined by the Compensation Committee. The Compensation Committee’s determinations under the 2023 Plan are conclusive and binding. The Compensation Committee may delegate certain of its duties, powers, and responsibilities as it deems appropriate to one or more of its members (or one or more other members of the Board, including the full Board), our officers, or our employees.
Term. No awards will be made after June 20, 2033, but previously granted awards may continue beyond that date in accordance with their terms. No awards which are intended to be incentive stock options (ISO) may be granted after the 10th anniversary of the date of the Plan's adoption by the Board.
Authorized Shares. Prior to the adoptionamendment of the 2023 Plan, and subject to adjustment upon certain changes in our capitalization as described in the 2023 Plan, the maximum aggregate number of shares of our common stock that may be delivered in satisfaction of awards consisted of an aggregate of approximately 159,000available for issuance under the 2023 Plan was equal to (i) 3,500,000 shares, and anyplus (ii) 184,904 shares that would otherwise have becomewere previously available for grant under the Company’s 2016 Equity Incentive Plan (the 2016 Plan) that were transferred to the 2023 Plan on June 20, 2023, plus (iii) any shares granted under the Company’s 2008 Equity Incentive Plan or 2016 Plan (collectively, the Prior Plans) that, on or after the Board’s adoptioneffective date of the 2023 Plan, become available as a result of the termination or forfeiture of awards under the 2008Plan or the 2016 Plan. AsPrior Plans. Our stockholders are being asked to approve an increase of the Date of Adoption, there were 159,0004,000,000 shares available for the grant of future equity awardsissuance under the 20162023 Plan. UnderIf our stockholders approve this increase, the maximum number of shares under clause (i) above that may be issued under the 2023 Plan there will be 3,500,000 shares available, plus, upincreased to 159,000 shares that remained available for grant under the 2016 Plan as of the Date of Adoption (less any shares underlying equity awards granted between the Date of Adoption and stockholder approval of the plan), plus any shares that would otherwise have become available for grant under the 2008 Plan and 2016 Plan after the Date of Adoption as a result of the termination or forfeiture of awards under the 2008 Plan and 2016 Plan, subject to adjustment to prevent the dilution or enlargement of rights from stock dividends, stock splits, recapitalization or similar transactions.7,500,000 shares.
41
The number of shares of common stock delivered in satisfaction of awards under the 2023 Plan will beis determined by (i) including shares withheld by us in payment of the exercise price or purchase price of the award or in satisfaction of tax withholding requirements with respect to the award, (ii) including the full number of shares covered by stock appreciation rights (SARs) any portion of which is settled in common stock (and not only the number of shares delivered in settlement) and (iii) by excluding any shares underlying awards that expire, become un-exercisable, terminate or are forfeited to or repurchased by us without the issuance of common stock. The number of shares available for delivery under the 2023 Plan will not be increased by the amount of any shares delivered under the plan that are subsequently repurchased using proceeds directly attributable to stock option exercises. Shares
delivered under the 2023 Plan may be authorized but unissued shares or previously issued shares of our common stock acquired by us. Shares issued under awards in substitution for equity awards of an acquired company that are converted, replaced or adjusted in connection with the acquisition will not reduce the number of shares available for awards under the 2023 Plan.
Annual Non-Employee Director Limits. The aggregate value of all compensation granted or paid to any non-employee director with respect to any calendar year, including all awards granted under the 2023 Plan and any other fees or compensation paid to such director outside of the 2023 Plan for services as a director, will not exceed $750,000$1,100,000 (currently $750,000) in the director's initial year and $500,000$850,000 (currently $500,000) in subsequent years. This limit does not apply to any award or shares of stock granted pursuant to a director’s election to receive an award or shares in lieu of cash retainers or other fees.fees (to the extent such award or shares have a fair value equal to the value of such cash retainers or other fees). The Board may make an exception to such limit for any director in extraordinary circumstances, as the Board may determine in its discretion, provided that any director who is granted or paid such additional compensation may not participate in the decision to grant or pay such additional compensation.
Eligibility. The Compensation Committee selects participants from among the key employees and directors of and consultants and advisors to us and our affiliates. Eligibility for incentive stock options (ISOs) is limited to our employees and employees of certain of our affiliates and eligibility for stock options other than ISOs is limited to individuals providing direct services to us or a subsidiary on the date of grant or who we reasonably anticipate will begin providing direct services to us or a subsidiary of ours within twelve months following the date of grant. As of April 21, 2023, 14223, 2024, 134 employees and seven8 non-executive directors would beare eligible to participate in the 2023 Plan. On April 21, 2023,23, 2024, the closing price of a share of our common stock was $9.00.$17.57.
Types of Awards. The 2023 Plan provides for grants of stock options, SARs, restricted and unrestricted stock and stock units, performance awards, other awards convertible into or otherwise based on shares of our stock, and cash awards. Dividend equivalents may also be provided in connection with awards under the 2023 Plan, provided that dividends and dividend equivalents payable or credited with respect to an award may not vest or be paid unless and until the award becomes vested. Awards may be settled in shares of our common stock, cash, property, other awards or a combination thereof.
Stock Options and SARs. The 2023 Plan provides for the grant of ISOs, non-qualified stock options (NSOs), and SARs. The exercise price of an option, and the base price against which a SAR is to be measured, may not be less than the fair market value (or, in the case of an ISO granted to a 10-percent stockholder, 110% of the fair market value) of a share of our common stock on the date of grant. The Compensation Committee determines when stock options or SARs become exercisable and the terms on which such awards remain exercisable. Stock options and SARs may have a maximum term of no more than ten years from the date of grant (or five years from the date of grant in the case of an ISO granted to a 10-percent stockholder).
Restricted and Unrestricted Stock. A restricted stock award is an award of our common stock subject to restrictions requiring that it be redelivered or offered for sale to us if specified conditions are not met, while an unrestricted stock award is not subject to restrictions.
Stock Units. A stock unit award is an unfunded and unsecured promise, denominated in shares of our common stock, and entitles the participant to receive stock or cash measured by the value of the shares in the future. The delivery of common stock or cash under a stock unit may be subject to the satisfaction of performance or other vesting conditions.
Performance Awards. A performance share award is an award the vesting, settlement or exercisability of which is subject to specified performance criteria.
Cash Awards. A cash award is an award denominated in cash.
Vesting. The Compensation Committee has the authority to determine the vesting schedule applicable to each award, and to accelerate the vesting or exercisability of any award.
Termination of Employment or Service. The Compensation Committee determines the effect of termination of employment or service on an award. Unless otherwise provided by the Compensation Committee, upon a termination of employment or service, all unvested stock options and other unvested awards will be forfeited and all vested stock options and SARs will remain exercisable for the lesser of the remaining term of the award and, in the case of a termination due to death, one year following the participant’s death, or, in the
42
case of a termination for any other reason, three months following termination. Notwithstanding the foregoing, upon a termination of employment or service for “Cause” (as defined in the 2023 Plan) or in circumstances that would have constituted grounds for “Cause,” all stock options and SARs, whether or not exercisable, will terminate upon cessation of employment.
Transferability. Awards under the 2023 Plan generally may not be transferred except by will or by the laws of descent and distribution. The Compensation Committee may permit the gratuitous transfer of awards other than ISOs.
Corporate Transactions. In the event of a consolidation, merger or similar transaction or series of related transactions, a sale, or transfer of all or substantially all of our assets or a dissolution or our liquidation (a Covered Transaction), the Compensation Committee may, among other things, provide for the continuation or assumption of outstanding awards, for new grants in substitution of outstanding awards, for the accelerated vesting or delivery of shares of common stock under awards or for a cash out of outstanding awards, in each case on such terms and with such restrictions as it deems appropriate. Except as the Compensation Committee may otherwise determine, awards not assumed or substituted will terminate upon the consummation of such Covered Transaction.
Adjustment. In the event of certain corporate transactions (including, but not limited to, a stock dividend, stock split or combination of shares (including a reverse stock split), recapitalization or other change in our capital structure that constitutes an equity restructuring within the meaning of Financial Accounting Standards Board (FASB) ASC Topic 718), the Compensation Committee will make appropriate adjustments to the maximum number of shares that may be issued under and the individual limits included in the 2023 Plan, and will also make appropriate adjustments to the number and kind of shares of stock or securities underlying equity awards, the exercise or purchase prices (or base values) of awards and any other terms of awards affected by such change. The Compensation Committee may also make the types of adjustments described above to take into account distributions to stockholders and events other than those listed above if it determines that such adjustments are appropriate to avoid distortion in the operation of the 2023 Plan.
Recoupment. The Compensation Committee may provide that outstanding awards, whether or not vested or exercisable, and the proceeds from the exercise or disposition of awards or stock acquired under awards will be subject to forfeiture and disgorgement to us, with interest and other related earnings, if the participant to whom the award was granted violates a non-competition, non-solicitation, confidentiality, or other restrictive covenant or any of our policies that provides for forfeiture or disgorgement with respect to incentive compensation that includes awards under the 2023 Plan. In addition, the Administrator may require forfeiture and disgorgement to us of outstanding awards and the proceeds from the exercise or disposition of awards or stock acquired under awards, with interest and other related earnings, to the extent required by law, including, without limitation, Section 10D of the Exchange Act, or applicable stock exchange listing standards and any of our related corporate policies.
Amendment and Termination. The Compensation Committee can amend the 2023 Plan or outstanding awards issued under the 2023 Plan, or terminate the 2023 Plan as to future grants of awards, at any time except that the Compensation Committee will not be able to alter the terms of an award without a participant’s consent if it would materially and adversely affect the participant’s rights under the award (unless expressly reserved by the Compensation Committee at the time of grant). Stockholder approval will be required for any amendment to the extent such approval is required by law, including the Code and applicable stock exchange requirements.
No Repricing. Except in connection with a corporate transaction involving the Company, the Company may not, without obtaining stockholder approval, (x) amend the terms of outstanding stock options or SARs to reduce the exercise price or base value of such stock options or SARs, (y) cancel outstanding stock options or SARs in exchange for stock options or SARs with an exercise price or base value that is less than the exercise price or base value of the original stock options or SARs, or (z) cancel outstanding stock options or SARs that have an exercise price or base value greater than the fair market value of a share of the Company’s common stock on the date of such cancellation in exchange for cash or other consideration.
New Plan Benefits
At its December 14, 2022No awards have been granted pending stockholder approval and February 22,as benefits under the 2023 meetings,Plan will depend on the Compensation CommitteeCommittee’s actions and the fair market value of common stock at various future dates, it is not possible to determine the benefits that will be received by executive officers, directors and other employees if the proposed 2023 Plan Amendment is approved by the stockholders.
Prior Grants Under the Plan
The following table sets forth, with respect to the individuals and groups named below, the aggregate number of shares subject to restricted stock unit awards to our Named Executive Officersunits and senior management and annual stock option awards to our non-executive directors, that, as a result, are subject to stockholder approval of this proposed 2023 Plan. These awards are summarized in the table below. No other awards have beenoptions previously granted under the 2023 Plan that are subject to stockholder approval(whether or not outstanding, vested or forfeited, as applicable) as of this proposed 2023 Plan.
2023 Long-Term Incentive Plan |
| |||||||||||||||
|
| Stock Options |
|
| Restricted Stock Units |
| ||||||||||
Name and Position |
| Dollar |
|
| Number of |
|
| Dollar |
|
| Number of |
| ||||
Nancy Lurker, Chief Executive Officer |
|
| — |
|
|
| — |
|
|
| 734,804 |
|
|
| 225,400 |
|
Jay Duker, President and Chief Operations Officer |
|
| — |
|
|
| — |
|
|
| 203,359 |
|
|
| 62,380 |
|
Michael Pine, Chief Corporate Development and Strategy Officer |
|
| — |
|
|
| — |
|
|
| 149,487 |
|
|
| 45,855 |
|
Total Executive Officers |
|
| — |
|
|
| — |
|
|
| 1,087,650 |
|
|
| 333,635 |
|
Non-Executive Director Group |
|
| — |
|
|
| 236,100 |
| (1) |
| — |
|
|
| — |
|
Non-Executive Officer Employee Group |
|
| — |
|
|
| — |
|
|
| 1,046,411 |
|
|
| 320,985 |
|
All Other Employees |
|
| — |
|
|
| — |
|
|
| 1,115,083 |
|
|
| 342,050 |
|
April 23, 2024. The stock options in the table above (1) have an exercise price of $3.26 per share of our common shares as to 157,600 options, the closing price on January 6, 2023 and $3.50 per share as to 78,500 options, the closing price on February 23, 2023, and both grants would vest on the first
anniversary of thesuch date of grant. Each stock option will expire no later than 10 years from the grant date. The restricted stock unit awards to our executive officers, the non-executive officer employee group and the all other employees group would vest ratably on an annual basis over three years from the January grant date. The amounts in the “Dollar Value” column in the table above represent the aggregate grant date fair value of the restricted stock unit awards computedwas $17.57, based on the closing share price as of $3.26 on January 6, 2023. The dollar value in accordance with FASB ASC Topic 718 will be determined based on the closing share price on June 20, 2023 following an approval of the 2023 Plan. We expect further additions to headcount during 2023. It is not possible to predict the individuals who will receive future awards under the 2023 Plan or the number of shares of common stock covered by any future award because such awards are wholly within the discretion of our Compensation Committee and our Board.April 23, 2024.
43
2023 Long-Term Incentive Plan |
| |||||||||
|
|
|
|
|
|
| ||||
Name and Position |
|
| Number of |
|
|
| Number of |
| ||
Named Executive Officers |
|
|
|
|
|
|
|
| ||
Jay Duker, President and Chief Executive Officer |
|
|
| 280,000 |
|
|
|
| 202,380 |
|
Nancy Lurker, Executive Vice Chair of the Board of Directors |
|
|
| 143,666 |
|
|
|
| 296,734 |
|
George Elston, SVP And CFO |
|
|
| 90,000 |
|
|
|
| 120,855 |
|
Dario Paggiarino, CMO |
|
|
| 42,000 |
|
|
|
| 66,855 |
|
Directors and Director Nominees |
|
|
|
|
|
|
|
| ||
Göran Ando |
|
|
| 64,198 |
|
|
|
| — |
|
John Landis |
|
|
| 84,114 |
|
|
|
| 10,000 |
|
David Guyer |
|
|
| 64,114 |
|
|
|
| — |
|
Wendy DiCicco |
|
|
| 64,114 |
|
|
|
| — |
|
Ye Liu |
|
|
| — |
|
|
|
| — |
|
Anthony P. Adamis |
|
|
| 64,114 |
|
|
|
| — |
|
Karen Zaderej |
|
|
| 64,114 |
|
|
|
| — |
|
Stuart Duty |
|
|
| 85,014 |
|
|
|
| — |
|
All current executive officers as a group (3 persons) |
|
|
| 513,666 |
|
|
|
| 619,969 |
|
All current non-employee directors as a group (8 persons) |
|
|
| 489,782 |
|
|
|
| 10,000 |
|
All current and former employees, including current officers who are not executive officers, as a group |
|
|
| 933,900 |
|
|
|
| 980,630 |
|
U.S. Federal Income Tax Consequences under the 2023 Plan
The following is a summary of some of the material U.S. federal income tax consequences associated with the grant and exercise of awards under the 2023 Plan under current U.S. federal tax laws and certain other tax considerations associated with awards under the 2023 Plan as of the date hereof. The summary does not address tax rates or non-U.S. or U.S. state or local tax consequences, nor does it address employment tax or other U.S. federal tax consequences, except as noted.
ISOs. In general, a participant realizes no taxable income upon the grant or exercise of an ISO. However, the exercise of an ISO may result in an alternative minimum tax liability to the participant. With some exceptions, a disposition of shares purchased under an ISO within two years from the date of grant or within one year after exercise produces ordinary income to the participant (and generally a tax deduction to us) equal to the value of the shares at the time of exercise less the exercise price. Any additional gain recognized in the disposition is treated as a capital gain for which we are not entitled to a deduction. If the participant does not dispose of the shares until after the expiration of these one- and two-year holding periods, generally any gain or loss recognized upon a subsequent sale is treated as a long-term capital gain or loss for which we are not entitled to a deduction.
NSOs. In general, a participant has no taxable income upon the grant of an NSO but realizes taxable income in connection with exercise of the option in an amount equal to the excess (at time of exercise) of the fair market value of the shares acquired upon exercise over the exercise price. A corresponding tax deduction is generally available to us. Upon a subsequent sale or exchange of the shares, any recognized gain or loss is treated as a capital gain or loss for which we are not entitled to a deduction.
SARs. The grant of a SAR does not itself result in taxable income to a participant, nor does taxable income result merely because a SAR becomes exercisable. In general, a participant who exercises a SAR for shares of stock or receives payment in cancellation of a SAR will have ordinary income equal to the amount of any cash and the fair market value of any stock or other property received. A corresponding tax deduction is generally available to us at that time.
Restricted Stock. A participant who is awarded or purchases shares subject to a substantial risk of forfeiture generally does not have taxable income until the risk of forfeiture lapses. When the risk of forfeiture lapses, the participant has ordinary income equal to the excess of the fair market value of the shares at that time over the purchase price, if any, and a corresponding tax deduction is generally available to us in the same year that the participant recognizes ordinary income. However, a participant may make an election under Section 83(b) of the Code (83(b) election) to be taxed on restricted stock when it is acquired rather than later, when the substantial risk of forfeiture lapses. A participant who makes an effective 83(b) election will realize ordinary income equal to the fair market value of the shares as of the time of acquisition less any price paid for the shares. A corresponding tax deduction will generally be available to us in the same year that the participant recognizes ordinary income. If a participant makes an effective 83(b) election, no additional income results by reason of the lapsing of the restrictions.
For purposes of determining capital gain or loss on a sale of shares awarded under the 2023 Plan, the holding period in the shares begins just after the participant recognizes taxable income with respect to the transfer. The participant’s tax basis in the shares equals the amount paid for the shares plus any income realized with respect to the transfer. However, if a participant makes an effective 83(b)
44
election and later forfeits the shares, the tax loss realized as a result of the forfeiture is limited to the excess of what the participant paid for the shares (if anything) over the amount (if any) realized in connection with the forfeiture.
Unrestricted Stock. A participant who purchases or is awarded unrestricted stock generally has ordinary income equal to the excess of the fair market value of the shares at the time of such purchase or award, as applicable, over the purchase price, if any, and a corresponding tax deduction is generally available to us in the same year that the participant recognizes ordinary income.
Restricted Stock Units. The grant of a restricted stock unit does not itself generally result in taxable income. Participants are generally taxed upon settlement (and a corresponding tax deduction is generally available to us) of a restricted stock unit, unless he or she has made a proper election to defer the receipt of the shares (or cash if the award is cash settled) under Section 409A of the Code. If the shares delivered are restricted for tax purposes, the participant will instead be subject to the rules described above for restricted stock.
Certain Change of Control Payments. Under Sections 280G and 4999 of the Code, the vesting or accelerated exercisability of stock options or the vesting and payments of other awards in connection with a change of control of a corporation may be required to be valued and taken into account in determining whether participants have received compensatory payments, contingent on the change in control, in excess of certain limits. If these limits are exceeded, a substantial portion of amounts payable to the participant, including income recognized by reason of the grant, vesting, or exercise of awards may be subject to an additional 20% federal tax and may be non-deductible to us.
Section 162(m). Our ability to take any tax deduction with respect to awards under the 2023 Plan is subject to deductibility limitations under Section 162 (m) of the Code.
Proposed Amendment to the 2023 Long-Term Incentive Plan
Our Board has approved, and recommends for adoption by our stockholders, an amendment to the 2023 Plan (i) to increase the number of shares of common stock reserved for issuance under the 2023 Plan by 4,000,000 and (ii) to increase the individual non-employee director compensation limit contained therein to $850,000 for ongoing directors and $1,100,000 for new directors in any calendar year. The amendment would also increase the ISO limit from 3,500,000 to 7,500,000 to align with the Share Increase.
The effectiveness of the proposed amendment to our 2023 Plan is contingent upon stockholder approval. If our stockholders do not approve the amendment, the existing version of our 2023 Plan will remain in effect, unchanged.
Voting Standard
The approval of this Proposal No. 2 requires the affirmative vote of a majority of the votes properly cast on the matter. Broker non-votes and abstentions will have no effect on the outcome of this proposal.
Board Recommendation
THE BOARD RECOMMENDS THAT YOU VOTE FOR PROPOSAL NO. 2, TO APPROVE THE 2023 PLAN AMENDMENT PROPOSAL.
45
PROPOSAL 3
APPROVAL OF AMENDMENT TO 2019 EMPLOYEE STOCK PURCHASE PLAN
General
Upon the recommendation of the Compensation Committee, the Board of Directors has approved, subject to stockholder approval, an amendment to the 2019 Employee Stock Purchase Plan, as amended (2019 ESPP) to increase the number of shares authorized for issuance under the 2019 ESPP by 250,000 shares ("Second 2019 ESPP Amendment"). As of April 23, 2024, there were approximately 103,000 shares available for future issuance under the 2019 ESPP.
The purpose of the 2019 ESPP is to encourage and to enable eligible employees to acquire proprietary interests in the Company through the purchase and ownership of shares of our common stock. The 2019 ESPP is intended to benefit us and our stockholders by incentivizing participants to contribute to our success and to operate and manage our business in a manner that provides for our long-term growth and profitability and that benefits our stockholders and other important stakeholders. The 2019 ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code of 1986. The following description of certain features of the 2019 ESPP is qualified in its entirety by reference to the full text of (x) Amendment No. 2 to the 2019 ESPP and (y) the 2019 ESPP, each of which is filed as Annex "B" to this proxy statement.
Share Reserve
The 2019 ESPP currently authorizes the issuance of up to 360,000 shares of our common stock pursuant to purchase rights granted to our employees or to employees of any of our participating affiliates. If approved by our stockholders, the proposed amendment would increase the number of shares that may be issued under the ESPP by 250,000 shares, for a total of 610,000 shares.
Administration
The 2019 ESPP is administered under the direction of our Board of Directors, our Compensation Committee, or any other committee designated by our Board of Directors. Our Board of Directors has delegated full authority to administer the 2019 ESPP to its Compensation Committee. Among other things, the Compensation Committee has the authority to determine eligibility for participation in the 2019 ESPP, designate separate offerings under the plan, and construe, interpret and apply the terms of the plan.
Eligibility
All of our employees who are employed by us or our participating affiliates may be eligible to participate in the 2019 ESPP, provided that the following employees are among those that are ineligible under the 2019 ESPP: (i) employees whose customary employment is 20 hours or less per week; (ii) employees whose customary employment is for not more than five months in any calendar year; and (iii) employees who, after exercising their rights to purchase our common stock under the 2019 ESPP, would own 5% or more of our total combined voting power.
As of April 23, 2024, a total of 134 employees were eligible to participate in the 2019 ESPP. No employee may be granted rights to purchase shares of our common stock in any calendar year under the 2019 ESPP and under all other employee stock purchase plans (as defined in Code Section 423) in which such purchase rights are outstanding having an aggregate fair market value in excess of $25,000, determined. In addition, unless otherwise determined by our Compensation Committee, no employee may purchase more than 5,000 shares of our common stock in any one offering period.
Offering Periods
The 2019 ESPP is implemented through a series of offerings under which eligible employees are granted purchase rights to purchase our common stock on specified dates during such offerings. Our Compensation Committee determines offering periods of not more than 27 months and may permit periodic purchases of our common stock within a single offering period. Unless otherwise established by our Compensation Committee prior to the start of an offering period, the plan has two offering periods (with concurrent purchase periods) that commence each calendar year, and each offering period will be of approximately six months’ duration, with the first such offering period beginning on the first trading day of February and ending on the last trading day of the immediately following July, and the second such offering period beginning on the first trading day of August and ending on the last trading day of the immediately following January.
46
Payroll Deductions and Purchase Price
Generally, all employees, including executive officers, employed by us or by any of our participating affiliates, may participate in the 2019 ESPP and may contribute, normally through payroll deductions, up to 10% of their eligible compensation for the purchase of our common stock under the 2019 ESPP. Unless otherwise determined by our Compensation Committee, the purchase price per share of our common stock under the 2019 ESPP will be 85% of the lesser of the average of the high and low sales price of our common stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period (or, if the relevant offering period has multiple purchase periods, the last trading day of the relevant purchase period).
Limitations on the Sale of Shares
Our Compensation Committee has the right to (i) require that an employee not request that all or a part of the shares of our common stock purchased by the employee be reissued in the employee’s own name and shares be delivered to the employee until two years have elapsed since the offering date of the offering period in which the shares of our common stock were purchased and one year has elapsed since the day the shares of our common stock were purchased (holding period), (ii) require that any sales of our common stock during the holding period be performed through a licensed broker acceptable to us and (iii) limit sales or other transfers of shares of our common stock for up to two years from the date the employee purchases shares of our common stock under the 2019 ESPP.
Corporate Transactions
In the event that there occurs a change in our capital structure through such actions as a recapitalization, stock split, reverse stock split, spin-off, combination of shares, exchange of shares, stock dividend, or other distribution payable in capital stock, our Compensation Committee will make appropriate adjustments to the number and kind of shares that may be purchased, and the number and kind of shares for which options are outstanding, under the 2019 ESPP.
In the event of certain significant corporate transactions, including (i) a dissolution or liquidation, (ii) a merger, consolidation or reorganization where we are not the surviving entity, (iii) a sale of all or substantially all of our assets, or (iv) a merger or consolidation resulting in any person or entity owning more than 50% of the combined voting power of all classes of our capital stock, the 2019 ESPP and all elections outstanding under the 2019 ESPP will terminate, except for certain situations where, for instance, the parties make arrangements for the continuation or assumption of the 2019 ESPP. In the event of any such termination of the 2019 ESPP, the offering period and the purchase period will be deemed to have ended on the last trading day prior to such termination, and the options of each participant then outstanding will be deemed to be automatically exercised on such last trading day.
Amendment, Suspension, or Termination
The 2019 ESPP will terminate on the day before the 10th anniversary of the date of adoption of the 2019 ESPP by our Board of Directors, unless earlier terminated. The date of adoption was April 26, 2019. The 2019 ESPP was amended on June 22, 2021. Our Compensation Committee may amend, suspend, or terminate the 2019 ESPP; however, any such amendment, suspension, or termination may not materially impair any vested rights without the employee’s consent. Our Compensation Committee may not increase the number of shares reserved for issuance under the 2019 ESPP without stockholder approval.
U.S. Federal Income Tax Consequences under the ESPP
The following is a summary of some of the material U.S. federal income tax consequences associated with participation in the 2019 ESPP under current U.S. federal tax laws. The summary does not address tax rates or non-U.S. or U.S. state or local tax consequences, nor does it address employment-tax or other U.S. federal tax consequences, except as noted.
The 2019 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code, and options to make purchases under the 2019 ESPP are intended to qualify under the provisions of Section 423 of the Internal Revenue Code. Amounts withheld from a participant’s earnings under the 2019 ESPP will be taxable income to the participant in the year in which the amounts otherwise would have been received, but the participant will not be required to recognize additional income for U.S. federal income tax purposes either at the time the participant is deemed to have been granted an option to purchase our common stock on the grant date or when the option to purchase our common stock is exercised on the purchase date. No additional taxable income will be recognized for U.S. federal income tax purposes by a participant until the sale or other disposition of the shares of our common stock acquired under the 2019 ESPP. Upon such sale or disposition, the participant will generally be subject to tax in an amount that depends upon the length of time such shares are held by the participant prior to selling or disposing of them.
47
If a participant holds the shares of our common stock purchased under the 2019 ESPP for at least two years after the grant date and for at least one year from the purchase date of the shares of our common stock, when the participant sells or disposes of the shares of our common stock (a “qualifying disposition”), the participant will recognize as ordinary income an amount equal to the lesser of: (i) the excess of the fair market value of the shares of our common stock on the date of such sale or disposition over the purchase price or (ii) the fair market value of the shares of our common stock on the grant date multiplied by the discount percentage for stock purchases under the 2019 ESPP. Any additional gain will be treated as long-term capital gain. If the shares are held for the holding periods described above but are sold for a price that is less than the purchase price, there is no ordinary income, and the participant has a long-term capital loss for the difference between the sale price and the purchase price.
If a participant sells or disposes of the shares of our common stock purchased under the 2019 ESPP within two years after the grant date or before one year has elapsed since the purchase date (a “disqualifying disposition”), the participant will recognize as ordinary income an amount equal to the excess of the fair market value of the shares on the date the shares are purchased over the purchase price. Any additional gain or loss on such sale or disposition will be long-term or short-term capital gain or loss, depending on how long the shares were held following the date they were purchased by the participant prior to selling or disposing of them.
In connection with a qualifying disposition, the Company will not receive any deduction for U.S. federal income tax purposes with respect to those shares of our common stock or the option under which it was purchased. In connection with a disqualifying disposition, the Company will be entitled to a deduction in an amount equal to the amount that is considered ordinary income
New Plan Benefits
Because the number of shares of our common stock that may be purchased under the 2019 ESPP will depend on each participant’s voluntary election to participate and on the fair market value of our common stock at various future dates, the actual number of shares that may be purchased by any individual cannot be determined in advance.
Registration with the SEC
If the 2023 Plan2019 ESPP Amendment is approved by our stockholders, we intend to file a Registration Statement on Form S-8 relating to the issuance of the additional shares of common stock available under the 2023 Plan2019 ESPP with the SEC pursuant to the Securities Act of 1933, as amended.
Proposed Approval
Voting Standard
The approval of EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan
Our Board has approved, and recommends for adoption by our stockholders,this Proposal No. 3 requires the 2023 Plan, which will adjust the numberaffirmative vote of shares of common stock reserved for issuance to approximately 3,659,000 shares. This number of shares includes up to 159,000 shares that remained available for grant under the 2016 Plan asa majority of the Datevotes properly cast on the matter. Broker non-votes and abstentions will have no effect on the outcome of Adoption (less any shares underlying equity awards granted between the Date of Adoption and stockholder approval of the plan), plus any shares that would otherwise become available for grant under the 2008 Plan and the 2016 Plan after the Date of Adoption as a result of the termination or forfeiture of awards under the 2008 Plan and 2016 Plan.this proposal.
The effectiveness of the proposed 2023 Plan is contingent upon stockholder approval.
Board Recommendation
THE BOARD RECOMMENDS THAT YOU VOTE FOR PROPOSAL NO. 2,3, TO APPROVE THE 2023 PLAN.AMENDMENT TO THE EYEPOINT PHARMACEUTICALS, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE NUMBER OF SHARES RESERVED FOR ISSUANCE UNDER THE 2019 EMPLOYEE STOCK PURCHASE PLAN
48
PROPOSAL 34
ADVISORY VOTE ON EXECUTIVE COMPENSATION
As required under Section 14A of the Exchange Act, the Board is submitting a “say on pay” proposal for stockholder consideration. While the vote on executive compensation is nonbinding and advisory, the Board and the Compensation Committee value the opinion of our stockholders, and to the extent there is any significant vote against the executive officer compensation as disclosed in this proxy statement, we will consider our stockholders’ concerns and evaluate what actions may be appropriate to address those concerns. Our current policy is to provide stockholders with an opportunity to approve the compensation of our Named Executive Officers each year at the annual meeting of stockholders. It is expected that the next such vote will occur at the 20242025 annual meeting of stockholders.
Our Board and the Compensation Committee value the perspectives and concerns of our stockholders regarding executive compensation. We are therefore pleased to entertain stockholder views and receive comments about our executive compensation practices.
Our executives regularly hold meetings with stockholders, and participate in professional investor conferences, to hear stockholder views on our financial performance, strategic business plans, corporate governance, executive compensation and related subjects. While we have not received particular stockholder feedback that warranted significant actions be undertaken to change our executive compensation program and practices, we will continue to regularly engage with stockholders and entertain their views, and also consult with professional advisors, regarding our Named Executive Officer compensation practices in the future.
The compensation of our Named Executive Officers is described starting on page 1625 of this proxy statement.
We are asking stockholders to vote on the following resolution:
“RESOLVED, that the Company’s stockholders approve, on an advisory basis, the compensation of our Named Executive Officers as disclosed in the proxy statement for the 20232024 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission.”
Voting Standard
The approval of this Proposal No. 4 requires the affirmative vote of a majority of the votes properly cast on the matter. Broker non-votes and abstentions will have no effect on the outcome of this proposal.
Board Recommendation
THE BOARD RECOMMENDS THAT YOU VOTE, ON AN ADVISORY BASIS, FOR PROPOSAL NO. 34 TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THIS PROXY STATEMENT.
49
PROPOSAL 45
RATIFICATION OF APPOINTMENT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Audit Committee has appointed Deloitte to serve as our independent registered public accounting firm and to audit our financial statements and our internal control over financial reporting for fiscal 2023.2024. Although ratification is not required, we are seeking stockholder approval of the selection as a matter of good corporate practice. If stockholders do not ratify the appointment, then the Audit Committee will consider whether it is appropriate to select a different independent registered public accounting firm or to continue Deloitte’s appointment as our independent registered public accounting firm. Even if stockholders do ratify the appointment, the Audit Committee in its discretion may select a different independent registered public accounting firm at any time during the year, if the Audit Committee determines that such a change would be in our and our stockholders’ best interests.
Deloitte was our independent registered public accounting firm for the fiscal years ended December 31, 20222023 and December 31, 2021.2022. Deloitte is expected to have a representative present at the Annual Meeting to answer appropriate questions and to make a statement if he or she desires.
Voting Standard
The approval of this Proposal No. 5 requires the affirmative vote of a majority of the votes properly cast on the matter. Broker non-votes will not occur in connection with this proposal because brokers, banks, trustees and other nominees have discretionary voting authority to vote shares on this proposal under stock exchange rules without specific instructions from the beneficial owner of such shares. Abstentions will have no effect on the outcome of this proposal.
Board Recommendation
THE BOARD RECOMMENDS THAT YOU VOTE FOR PROPOSAL NO. 45 TO RATIFY OUR SELECTION OF DELOITTE AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL 2023.2024.
Accounting Fees and Services
The following table sets forth the total fees paid to Deloitte and its affiliates with respect to the years ended December 31, 20222023 and December 31, 20212022 (in thousands):
|
| Year Ended December 31, |
|
| Year Ended December 31, |
| ||
|
| 2022 |
|
| 2021 |
| ||
Audit fees(1) |
| $ | 780 |
|
| $ | 819 |
|
Tax fees(2) |
|
| 315 |
|
|
| 113 |
|
All other fees(3) |
|
| 2 |
|
|
| 2 |
|
| $ | 1,097 |
|
| $ | 934 |
|
|
| Year Ended December 31, |
|
| Year Ended December 31, |
| ||
|
| 2023 |
|
| 2022 |
| ||
Audit Fees(1) |
| $ | 1,062 |
|
| $ | 780 |
|
Tax Fees(2) |
|
| 294 |
|
|
| 315 |
|
All Other Fees(3) |
|
| 2 |
|
|
| 2 |
|
| $ | 1,358 |
|
| $ | 1,097 |
|
Our policies require the Audit Committee to pre-approve all audit and permitted non-audit services provided by the independent registered public accounting firm, including engagement fees and terms. The Audit Committee may delegate pre-approval authority to one or more of its members, who will report any pre-approval decisions to the full committee at its next scheduled meeting but may not delegate pre-approval authority to members of management. The Audit Committee may approve only those non-audit services classified as “all other services” that it believes to be routine and recurring services, to be consistent with SEC rules and to not impair the auditor’s independence with respect to us. The Audit Committee reviewed and pre-approved all audit services and permitted non-audit services performed during the years ended December 31, 20222023 and 2021.2022.
50
The Company’s principal accountant for the periods presented above did not engage any other persons or firms other than the principal accountant’s full-time, permanent employees.
51
INFORMATION ABOUT STOCKHOLDER PROPOSALS AND DIRECTOR NOMINATIONS
Stockholder proposals for inclusion in our proxy statement: To be eligible for inclusion in our proxy statement and form of proxy relating to our 20242025 Annual Meeting of Stockholders (2024(2025 Annual Meeting), stockholder proposals must be submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended, and received at our principal executive offices no later than January 6, 2024,2025, which is 120 calendar days before May 5, 2024—6, 2025—the anniversary of the date this proxy statement was released to stockholders in connection with the Annual Meeting. If the date of the 20242025 Annual Meeting is changed by more than 30 days from the anniversary date of this year’s Annual Meeting on June 20, 2023,2024, then the deadline is a reasonable time before we begin to print and mail proxy materials.
Other stockholder proposals: A nomination of one or more persons for election as a director or any other stockholder proposal not included in our proxy statement for the 20242025 Annual Meeting will be ineligible for presentation at the meeting unless the stockholder gives timely notice of the proposal in writing to our Company Secretary at our principal executive offices and otherwise complies with the provisions of our By-Laws. To be timely, our By-Laws provide that we must receive the stockholder’s notice: (i) not less than 60 days in advance of the meeting if the meeting is to be held on a day which is within 30 days preceding the anniversary of the 20232024 Annual Meeting, (ii) not less than 90 days in advance of the meeting if the meeting is to be held on or after the anniversary of the 20232024 Annual Meeting, and (iii) in any other cases, not more than 15 days following the date on which notice or public disclosure (as(such date as defined in our By-Laws) of the date of the 20242025 Annual Meeting is made.
In addition to satisfying the foregoing requirements, to comply with the universal proxy rules (once effective), stockholders who intend to solicit proxies in support of director nominees other than the Company’s director nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than April 22, 2024.21, 2025, which is 60 days prior to the one-year anniversary date of the Annual Meeting.
We reserve the right to reject, rule out of order or take other appropriate action with respect to any proposal that does not comply with the foregoing requirements and with the SEC regulations regarding stockholder proposals.
DELIVERY OF DOCUMENTS TO STOCKHOLDERS SHARING AN ADDRESS
We have adopted a procedure, approved by the SEC, called “householding.” Under this procedure, stockholders of record who have the same address and last name may receive only one Notice of Internet Availability of Proxy Materials, unless we are notified that one or more of these stockholders wishes to continue receiving individual copies. This procedure will reduce our printing costs and postage fees.
If you are eligible for householding, but you and other stockholders of record with whom you share an address currently receive multiple copies of the Notice of Internet Availability of Proxy Materials, or if you hold our stock in more than one account, and in either case you wish to receive only a single copy of the Notice of Internet Availability of Proxy Materials for your household, please contact our Company Secretary by mail, c/o EyePoint Pharmaceuticals, Inc., 480 Pleasant Street, Suite C400, Watertown, MA 02472, or by phone at (617) 926-5000. If you participate in householding and wish to receive a separate copy of the Notice of Internet Availability of Proxy Materials, or if you do not wish to continue to participate in householding and prefer to receive separate copies of this document in the future, please contact our Company Secretary as indicated above.
If your shares are held in street name through a broker, bank or other intermediary, please contact your broker, bank or intermediary directly if you have questions, require additional copies of our proxy materials or wish to receive a single copy of such materials in the future for all beneficial owners of shares of our common stock sharing an address.
AVAILABILITY OF ANNUAL REPORT ON FORM 10-K
A copy of our Annual Report on Form 10-K for the year ended December 31, 20222023 has been posted on the Internet along with this proxy statement, each of which is accessible by following the instructions in the Notice of Internet Availability of Proxy Materials. The Annual Report on Form 10-K is not incorporated into this proxy statement and is not considered proxy-soliciting material.
We filed our Annual Report on Form 10-K with the SEC on March 10, 2023.8, 2024. We will mail without charge, upon request, a copy of our Annual Report on Form 10-K for the year ended December 31, 2022,2023, excluding the exhibits thereto. We will provide copies of the exhibits to the Form 10-K upon request by eligible stockholders, provided that we may impose a reasonable fee for providing such exhibits, which is limited to our reasonable expenses. Requests for copies of the Annual Report on Form 10-K or such exhibits should be mailed to our Company Secretary by mail, c/o EyePoint Pharmaceuticals, Inc., 480 Pleasant Street, Suite C400, Watertown, MA 02472.
52
OTHER BUSINESS
As of the date of this Proxy Statement, we do not know of any other matter that properly may come before the Annual Meeting, and do not intend to present any other matter. However, if any other matters properly come before the meeting or any adjournment, the persons named as proxies will be able to vote on those matters in accordance with their own judgment.
If there are insufficient votes to approve the proposals, your proxy may be voted by the persons named in the proxy to adjourn the Annual Meeting in order to solicit additional proxies in favor of the approval of such proposals. If the Annual Meeting is adjourned or postponed for any purpose, at any subsequent reconvening of the meeting your proxy will be voted in the same manner as it would have been voted at the original convening of the Annual Meeting unless you withdraw or revoke your proxy. Your proxy may be voted in this manner even though it may have been voted on the same or any other matter at a previous session of the Annual Meeting.
53
ANNEX A
EYEPOINT PHARMACEUTICALS, INC.
AMENDMENT NO. 1 TO THE 2023 Long Term INCENTIVE PLAN
WHEREAS, EyePoint Pharmaceuticals, Inc. (the “Company”) maintains the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan, effective as of June 20, 2023 (the “Plan”);
WHEREAS, pursuant to Section 9 of the Plan, the Compensation Committee (“Compensation Committee”) of the Board of Directors of the Company (the “Board”) may amend the Plan at any time; provided that, amendments to the Plan must be approved by the Company’s stockholders if and to the extent required by applicable laws or stock exchange requirements (“Stockholder Approval”);
WHEREAS, the Compensation Committee, in consultation with legal and financial advisors, has determined that it is advisable and in the best interests of the Company and its stockholders to (i) increase the number of shares of the Company’s common stock, $0.001 par value per share, reserved for issuance under the Plan by 4,000,000 shares (the “Share Increase”) and (ii) increase the individual non-employee director compensation limit contained therein to $850,000 for ongoing directors in any calendar year and $1,100,000 for new directors in any calendar year (the “Director Compensation Increase”);
WHEREAS, pursuant to Section 9 of the Plan, in order to effect the Share Increase, Stockholder Approval must be obtained;
WHEREAS, the Compensation Committee has approved the Share Increase and the Director Compensation Increase and has recommended that the Board adopt and approve the Share Increase and the Director Compensation Increase subject to Stockholder Approval;
WHEREAS, the Board desires to amend the Plan to provide for the Share Increase and the Director Compensation Increase as set forth in this amendment to the Plan (this “Amendment”), effective upon receipt of the Stockholder Approval; and
WHEREAS, capitalized terms used in this Amendment but not defined herein shall have the meaning given to them in the Plan.
NOW, THEREFORE, the Board hereby amends the Plan, effective upon receipt of the Stockholder Approval, as follows:
1. Section 4(a) of the Plan is deleted and replaced in its entirety with the following:
4. LIMITS ON AWARDS UNDER THE PLAN.
“(a) Number of Shares. Subject to adjustment as provided in Section 7(b), the maximum number of shares of Stock that may be issued in satisfaction of Equity Awards under the Plan is 7,500,000, plus 184,904 shares of Stock that were previously available for grant under the 2016 Plan that were transferred to the Plan as of June 20, 2023, plus any shares of Stock that would otherwise have become available for grant under the Prior Plans after the Date of Adoption as a result of the termination or forfeiture of awards under the Prior Plans. Up to 7,500,000 shares of Stock set forth in the preceding sentence may be issued in satisfaction of ISOs, but nothing in this Section 4(a) will be construed as requiring that any, or any fixed number of, ISOs be awarded under the Plan. For purposes of this Section 4(a), the number of shares of Stock issued in
A-1
satisfaction of Equity Awards will be determined (i) by including shares of Stock withheld by the Company in payment of the exercise price or purchase price of the Award or in satisfaction of tax withholding requirements with respect to the Award, (ii) by including the full number of shares covered by a SAR any portion of which is settled in Stock (and not only the number of shares of Stock delivered in settlement), and (iii) by excluding any shares of Stock underlying Awards that expire, become unexercisable, terminate or are forfeited to or repurchased by the Company without the issuance of Stock. For the avoidance of doubt, the number of shares of Stock available for delivery under the Plan will not be increased by any shares of Stock delivered under the Plan that are subsequently repurchased using proceeds directly attributable to Stock Option exercises. The limits set forth in this Section 4(a) will be construed to comply with Section 422. To the extent consistent with the requirements of Section 422 and the regulations thereunder, and other applicable legal requirements (including applicable stock exchange requirements), Stock issued under Substitute Awards will not reduce the number of shares available for Awards under the Plan. The number of shares of Stock that may be delivered under substitute Awards will be in addition to the limitations set forth in this Section 4(a) on the number of shares available for issuance under the Plan."
2. Section 4(c) of the Plan is deleted and replaced in its entirety with the following:
4. LIMITS ON AWARDS UNDER THE PLAN.
“(c)Limitations on Awards to Directors. The aggregate value of all compensation granted or paid to any Director with respect to any calendar year, including all Awards granted under the Plan and any other fees or compensation paid to such Director outside of the Plan for his or her services as a Director during such calendar year, will not exceed $850,000 in the aggregate (except that for the first calendar year in which such Director becomes a Director such value will not exceed $1,100,000 in the aggregate), in each case calculating the value of any Awards in accordance with FASB ASC Topic 718 (or any successor provision), assuming maximum performance (if applicable). The Board may make an exception to such limit for any Director in extraordinary circumstances, as the Board may determine in its discretion, provided that any Director who is granted or paid such additional compensation may not participate in the decision to grant or pay such additional compensation. The limitations applicable to Director Awards will not apply to any Award or shares of Stock granted pursuant to a Director’s election to receive an Award or shares of Stock in lieu of cash retainers or other fees (to the extent such Award or shares of Stock have a fair value equal to the value of such cash retainers or other fees)."
3. Except as specifically provided in and modified by this Amendment, the Plan is in all other respects hereby ratified and confirmed and references to the Plan shall be deemed to refer to the Plan as modified by this Amendment, effective upon receipt of the Stockholder Approval.
A-2
EYEPOINT PHARMACEUTICALS, INC.
2023 Long Term INCENTIVE PLAN
Exhibit A, which is incorporated by reference, defines the terms used in the Plan and includes certain operational rules related to those terms.
The Plan has been established to advance the interests of the Company by providing for the grant to Participants of Stock, Stock-based and other incentive Awards.
The Administrator has discretionary authority, subject only to the express provisions of the Plan, to interpret the Plan; determine eligibility for and grant Awards; determine, modify or waive the terms and conditions of any Award; determine the form of settlement of Awards (whether in cash, shares of Stock, or other property); prescribe forms, rules and procedures relating to the Plan and Awards; and otherwise do all things necessary or desirable to carry out the purposes of the Plan. Determinations of the Administrator made under the Plan will be conclusive and will bind all persons.
A-3
The Administrator will select Participants from among key Employees and Directors of, and consultants and advisors to, the Company and its Affiliates. Eligibility for ISOs is limited to individuals described in the first sentence of this Section 5 who are employees of the Company or of a “parent corporation” or “subsidiary corporation” of the Company as those terms are defined in Section 424 of the Code. Eligibility for SARs and Stock Options other than ISOs is limited to individuals described in the first sentence of this Section 5 who are providing direct services on the date of grant of the Award to the Company or a subsidiary of the Company that would be described in the first sentence of Treas. Regs. §1.409A-1(b)(5)(iii)(E) or to other individuals who the Company reasonably anticipates will begin providing direct services to the Company or a subsidiary of the Company within twelve (12) months following an Award’s date of grant.
A-4
A-5
A-6
A-7
A-8
A-9
The Company will not be obligated to deliver any shares of Stock pursuant to the Plan or to remove any restriction from shares of Stock previously delivered under the Plan until: (i) the Company is satisfied that all legal matters in connection with the issuance and delivery of such shares have been addressed and resolved; (ii) if the outstanding Stock is at the time of delivery listed on any stock exchange or national market system, the shares to be delivered have been listed or authorized to be listed on such exchange or system upon official notice of issuance; and (iii) all conditions of the Award have been satisfied or waived. The Company may require, as a condition to the exercise of an Award or the delivery of shares of Stock under an Award, such representations or agreements as counsel for the Company may consider appropriate to avoid violation of the Securities Act of 1933, as amended, or any applicable state or non-U.S. securities law. Any Stock required to be issued to Participants under the Plan will be evidenced in such manner as the Administrator may deem appropriate, including book-entry registration or delivery of stock certificates. In the event that the Administrator determines that stock certificates will be issued to Participants under the Plan, the Administrator may require that certificates evidencing Stock issued under the Plan bear an appropriate legend reflecting any restriction on transfer applicable to such Stock, and the Company may hold the certificates pending lapse of the applicable restrictions.
The Administrator may at any time or times amend the Plan or any outstanding Award for any purpose which may at the time be permitted by law, and may at any time terminate the Plan as to any future grants of Awards; provided, however, that except as otherwise expressly provided in the Plan the Administrator may not, without the Participant’s consent, alter the terms of an Award so as to affect materially and adversely the Participant’s rights under the Award, unless the Administrator expressly
reserved the right to do so at the time the Award was granted. Any amendments to the Plan will be conditioned upon shareholder approval only to the extent, if any, such approval is required by law (including the Code) or applicable stock exchange requirements, as determined by the Administrator.
The existence of the Plan or the grant of any Award will not affect the Company’s right to award a person bonuses or other compensation in addition to Awards under the Plan.
A-10
The Administrator may at any time and from time to time establish one or more sub-plans under the Plan (for local-law compliance purposes or other administrative reasons determined by the Administrator) by adopting supplements to the Plan containing, in each case, such limitations on the Administrator’s discretion under the Plan, and such additional terms and conditions, as the Administrator deems necessary or desirable. Each supplement so established will be deemed to be part of the Plan but will apply only to Participants within the group to which the supplement applies (as determined by the Administrator).
A-11
EXHIBIT A
Definition of TermsANNEX B
The following terms, when used in the Plan, will have the meanings and be subject to the provisions set forth below:
“Administrator”: EYEPOINT PHARMACEUTICALS, INC.The Compensation Committee, except that
AMENDMENT NO. 2 TO THE 2019 EMPLOYEE STOCK PURCHASE PLAN
WHEREAS, EyePoint Pharmaceuticals, Inc. (the “Company”) maintains the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan, which was originally effective as of July 1, 2019 and amended as of June 22, 2021 (as amended, the “ESPP”);
WHEREAS, pursuant to Section 13(b) of the ESPP, the Compensation Committee may delegate (i) to one or more of its members (or one or more other members(“Compensation Committee”) of the Board including the full Board) such of its duties, powers and responsibilities as it may determine; (ii) to one or more officersDirectors of the Company (the “Board”) may amend the powerESPP at any time; provided that, the effectiveness of any amendment to grant Awardsthe ESPP shall be contingent on approval of such amendment by the Company’s stockholders to the extent permittedprovided by Section 157(c)the Board or applicable law (“Stockholder Approval”);
WHEREAS, the Compensation Committee, in consultation with legal and financial advisors, has determined that it is advisable and in the best interests of the Delaware General Corporation Law;Company and (iii)its stockholders to such Employees or other personsincrease the number of shares of the Company’s common stock, $0.001 par value per share, reserved for issuance under the ESPP by 250,000 shares (the “ESPP Share Increase”);
WHEREAS, pursuant to Section 13(b) of the ESPP, in order to effect the ESPP Share Increase, Stockholder Approval must be obtained;
WHEREAS, the Compensation Committee has approved the ESPP Share Increase and has recommended that the Board adopt and approve the ESPP Share Increase subject to Stockholder Approval;
WHEREAS, the Board desires to amend the ESPP to provide for the ESPP Share Increase as it determines such ministerial tasks as it deems appropriate. Inset forth in this amendment to the eventESPP (this “ESPP Amendment”), effective upon receipt of any delegation describedthe Stockholder Approval; and
WHEREAS, capitalized terms used in this ESPP Amendment but not defined herein shall have the meaning given to them in the preceding sentence,ESPP.
NOW, THEREFORE, the term “Administrator” will includeBoard hereby amends the personESPP, effective upon receipt of the Stockholder Approval, as follows:
1. Section 3(a) of the ESPP is deleted and replaced in its entirety with the following:
3. SHARES SUBJECT TO THE PLAN
“(a) Share Reserve. Subject to adjustment as provided in Section 12, the maximum number of shares of Stock that may be issued pursuant to Options granted under the Plan (including any Non-423(b) Offering established hereunder) is Six-Hundred and Ten Thousand (610,000) shares. The shares of Stock reserved for issuance under the Plan may be authorized but unissued shares, treasury shares, or persons so delegatedshares purchased on the open market.”
2. Except as specifically provided in and modified by this ESPP Amendment, the ESPP is in all other respects hereby ratified and confirmed and references to the extent of such delegation.
“Affiliate”: Any corporation or other entity that stands in a relationshipESPP shall be deemed to refer to the ESPP as modified by this ESPP Amendment, effective upon receipt of the Stockholder Approval.
A-12
Conformed copy to reflect amendments adopted through June 22, 2021.
EYEPOINT PHARMACEUTICALS, INC.
2019 EMPLOYEE STOCKPURCHASE PLAN, AS AMENDED
“Award”: Any orCompany and to operate and manage the Company’s business in a combinationmanner that will provide for the Company’s long-term growth and profitability and that will benefit its stockholders and other important stakeholders and (b) by encouraging Participants to remain in the employ of the following:Company or its Participating Affiliates. The Plan was adopted by the Board on April 26, 2019 and was approved by the Company’s stockholders on June 25, 2019.
(iii) Restricted Stock.
(iv) Unrestricted Stock.
(v) Stock Units, including Restricted Stock Units.
(vi) Performance Awards.
(vii) Cash Awards.
“Cause”: CodeIn” shall mean the caseInternal Revenue Code of any Participant who is party to an employment or severance-benefit agreement that contains a definition of “Cause,” the definition set forth in such agreement will apply for Plan purposes for so long1986, as such agreement isamended, as now in effect or as hereafter amended, and any successor thereto.References in the Plan to any Code Section shall be deemed to include, as applicable, regulations and guidance promulgated under such Code Section.
A-13
A-14
A-15
A-16
A-17
A-18
A-19
Illustrative Hypothetical Example of the Purchase Price calculation
Offering Period: August 1, 2019 - January 31, 2020
Highsales price of EYPT Stock on August1, 2019: $2.30 Low sales price of EYPT Stock on August 1, 2019: $2.20
Average high and low sales price of EYPT Stock on August 1, 2019: $2.25
85% of average high and low sales price of EYPT Stock on August 1, 2019: $1.9125
High sales price of EYPT Stock on January 31, 2020: $3.50 Low sales price of EYPT Stock on January 31, 2020: $3.30
Average high and low sales price of EYPT Stock on January 31, 2020:$3.40
85% of average high and low sales price of EYPT Stock on January 31, 2020: $2.89
The lesser of the two 85% of average high and low sales price figures is $1.9125. Thus, the Purchase Price applicable for this hypothetical Offering Period is $1.9125 per Share of EYPT Stock.
A-20
A-21
A-22
duty of loyalty to the Company or its subsidiaries; (v) material breach of any of the terms of the Plan or any Award made under the Plan, or of the terms of anymore other agreement between the Company or subsidiaries and the Participant; or (vi) other conduct by the Participant that could be expected to be harmful to the business, interests or reputation of the Company.
“Code”: The U.S. Internal Revenue Code of 1986, as from time to time amended and in effect, or any successor statute as from time to time in effect.
“Compensation Committee”: The Compensation Committee of the Board.
“Company”: EyePoint Pharmaceuticals, Inc., a Delaware corporation.
“Covered Transaction”: Any of (i) a consolidation, merger, or similar transaction or series of related transactions, including a sale or other disposition of stock,corporations in which the Company is not the surviving corporation, or which results in the acquisitionupon a sale of all or substantially all of the Company’s then outstanding common stock by a singleassets of the Company to another corporation, or upon any merger or consolidation in which the Company is the surviving corporation that results in any person or entity or by a groupowning more than fifty percent (50%) of personsthe combined voting power of all classes of stock of the Company, the Plan and all Options outstanding hereunder shall terminate, except to the extent provision is made in writing in connection with such transaction for the continuation of the Plan and/or entities acting in concert, (ii) a sale or transfer of all or substantially all the Company’s assets, or (iii) a dissolution or liquidationassumption of the Company. WhereOptions theretofore granted, or for the substitution for such Option of new rights covering the stock of a Covered Transaction involvessuccessor corporation, or a tender offer that is reasonably expectedparent or subsidiary thereof, with appropriate adjustments as to be followed by a merger describedthe number and kinds of shares and purchase prices, in clause (i) (as determined bywhich event the Administrator),Plan and rights theretofore granted shall continue in the Covered Transaction willmanner and under the terms so provided. In the event of any such termination of the Plan, the Offering Period and the Purchase Period shall be deemed to have occurred upon consummationended on the last Trading Day prior to such termination, and in accordance with Section 9, the Options of the tender offer.
“Date of Adoption”: The earlier of the date the Plan was approved by the Company’s shareholders or adopted by the Board, as determined by the Committee.
“Director”: A member of the Board who is not an Employee.
“Employee”: Any person who is employed by the Company or an Affiliate.
“Employment”: A Participant’s employment or other service relationship with the Company and its Affiliates. Employment willeach Participant then outstanding shall be deemed to continue, unless thebe automatically exercised on such last Trading Day. The Administrator expressly provides otherwise, so long as the Participant is employed by, or otherwise is providing servicesshall send written notice of an event that will result in such a capacity described in Section 5termination to all Participants at least five (5) days prior to the Company or an Affiliate. If a Participant’s employment or other service relationship is with an Affiliate and that entity ceases to be an Affiliate,date upon which the Participant’s EmploymentPlan will be deemedterminated.
A-23
“Equity Award”: An Award other than a Cash Award.
“Fair Market Value”: As of a particular date, (i) the closing price for a share of Stock reported on the NASDAQ Global Market (or any other national securities exchange on which the Stock is then listed) for that date or, if no closing price is reported for that date, the closing price on the immediately
preceding date on which a closing price was reported or (ii) in the event that the Stock is not traded on a national securities exchange, the fair market value of a share of Stock determinedmade by the Administrator, consistent with the ruleswhose determination in that respect shall be final, binding, and conclusive.
“ISO”: A Stockan Option intended to be an “incentive stock option” within the meaning of Section 422. Each Stock Option granted pursuant to the Plan willshall not affect or limit in any way the right or power of the Company to make adjustments, reclassifications, reorganizations, or changes of its capital or business structure or to merge, consolidate, dissolve or liquidate, or to sell or transfer all or any part of its business or assets.
“NSO”: A Stock Option that is not intended to be an “incentive stock option” within the meaning of Section 422.
“Participant”: A person who is granted an Award under the Plan.
“Performance Award”: An Award subject to Performance Criteria.
“Performance Criteria”: Specified criteria, other than the mere continuation of Employment or the mere passage of time, the satisfaction of which is a condition for the grant, exercisability, vesting or full enjoyment of an Award. A Performance Criterion and any targets with respect thereto need not be based upon an increase, a positive or improved result or avoidance of loss. A Performance Criterion will mean an objectively determinable measure or objectively determinable measures of performance including but not limited to any, or any combinationadoption of the following (measured either absolutely or comparatively (including, without limitation,Plan by reference to an index or indices or the performanceBoard (which was April 26, 2019), (ii) the date determined in accordance with Section 12, and (iii) the date determined in accordance with Section 13(b).
“Plan”: The EyePoint Pharmaceuticals, Inc. 2023 Long Term Incentive Plan, astime and from time to time, amended and in effect.
“Prior Plans”:amend, suspend, or terminate the Plan or an Offering Period under the Plan; provided, however, that no amendment, suspension, or termination shall, without the consent of the Participant, materially impair any rights of a Participant that have vested at the time of such amendment, suspension, or termination. The Amended and Restated Eyepoint Pharmaceuticals, Inc. 2016 Long Term Incentive Plan (the “2016 Plan”) and the pSivida Corp. 2008 Incentive Plan, as each is from time to time amended and in effect.
“Restricted Stock”: Stock subject to restrictions requiring that it be redelivered or offered for saleeffectiveness of any amendment to the Company if specified service- or performance-based conditions are not satisfied.
“Restricted Stock Unit”: A Stock Unit that is, or as to whichPlan shall be contingent on approval of such amendment by the delivery of Stock or cash in lieu of Stock is, subjectCompany’s stockholders to the satisfactionextent provided by the Board or required by applicable law.
“SAR”: A right entitling the holder upon exercise to receive an amount (payable in cash or intransfer of any shares of Stock of equivalent value) equalpurchased under the Plan, the Company may withhold amounts needed to cover such taxes from any payments otherwise due and owing to the excessParticipant or from shares that would otherwise be issued to the Participant under the Plan. Any Participant who sells or otherwise transfers shares of Stock purchased under the Plan within two (2) years after the beginning of the Fair Market Value ofOffering Period in which the shares were purchased or within one (1) year from the date the shares of Stock subjectwere purchased, must, within ten (10) days of such transfer, notify the Company in writing of such transfer.
“Section 409A”: Section 409Athe Participant (or, in the event of the Code.Participant’s death, to the Participant’s estate or, if the Administrator permits a beneficiary designation, the beneficiary or beneficiaries most recently designated by the Participant prior to his or her death). During a Participant’s lifetime, only such Participant may exercise his or her Options under the Plan.
“Stock”: Common stockPlan restrict or interfere in any way with the right of the Company par value $0.001 per share.or any of its Subsidiaries to terminate the Participant’s employment at any time.
A-24
“Substitute Awards”: EquityAwards issued under the Plan in substitution for equity awardsis subject to such approval of an acquired company that are converted, replacedany governmental authority and any national securities exchange or adjustedother market quotation system as may be required in connection with the acquisition.authorization, issuance, or sale of such shares.
***
A-25
MMMMMMMMMMMM MMMMMMMMM 000001 Please do not write outside the designated areas. EYEPOINT PHARMACEUTICALS ENDORSEMENT LINE SACKPACK MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 Using a black ink pen, mark your votes with an X as shown in this example. MMMMMMMMMMMMMMM C123456789 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext Your vote matters – here’s how to vote! You may vote online or by phone instead of mailing this card. Online Go to www.envisionreports.com/EYPT or scan the QR code — login details are located in the shaded bar below. Phone Call toll free 1-800-652-VOTE (8683) within the USA, US territories and Canada Save paper, time and money! Sign up for electronic delivery at www.envisionreports.com/EYPT Annaul Meeting Proxy Card 1234 5678 9012 345 IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. A The Board of Directors recommends you vote FOR ALL of the following nominees: 1. Election of Directors: 01 - Göran Ando 02 - Nancy S. Lurker 03 - John B. Landis 04 - David R. Guyer + 05 - Wendy F. DiCicco 06 - Ye Liu 07 - Anthony P. Adamis 08 - Karen Zaderej Mark here to vote FOR all nominees Mark here to WITHHOLD vote from all nominees For All EXCEPT - To withhold authority to vote for any nominee(s), write the name(s) of such nominee(s) below. B The Board of Directors recommends you vote FOR proposals 2,3 and 4. For Against Abstain For Against Abstain 2. To approve the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan, as disclosed in the accompanying Proxy Company’s named executive officers as disclosed in the statement. 3. To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement. 4. To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to be Held on June 20, 2023: The proxy statement and the Annual Report on Form 10-K for the twelve months ended December 31, 2022 are available at www.edocumentview.com/EYPT for street holders and www.envisionreports.com/EYPT for registered holders. C Authorized Signatures - This section must be completed for your vote to count. Please date and sign below. Please sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, corporate officer, trustee, guardian, or custodian, please give full title. Date (mm/dd/yyyy) — Please print date below. Signature 1 — Please keep signature within the box. Signature 2 — Please keep signature within the box. MR A SAMPLE (THIS AREA IS SET UP TO ACCOMMODATE C 1234567890 J N T 140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND 1UPX 575230 MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MMMMMMM + 03T1JF
The 2023 Annual Meeting of Stockholders of EyePoint Pharmaceuticals will be held on June 20, 2023 at 9:00 a.m. Eastern Time, virtually via the internet at www.meetnow.global/M2D47QY. To access the virtual meeting, you must have the information that is printed in the shaded bar located on the reverse side of this form. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to be held on June 20, 2023: The proxy statement and the Annual Report on Form 10-K for the twelve months ended December 31, 2022 are available at www.edocumentview.com/EYPT for street holders and www.envisionreports.com/EYPT for registered holders. Small steps make an impact. Help the environment by consenting to receive electronic delivery, sign up at www.envisionreports.com/EYPT IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. Proxy — EyePoint Pharmaceuticals, Inc. + Notice of 2023 Annual Meeting of Stockholders Proxy Solicited by the Board of Directors for the Annual Meeting of Stockholders — June 20, 2023 The undersigned hereby appoints Nancy S. Lurker and Ron I. Honig, and each of them, each with the full power of substitution, as proxies to represent and vote the shares of the undersigned, with all the powers which the undersigned would possess if personally present, at the Annual Meeting of Stockholders of EyePoint Pharmaceuticals, Inc. to be held on Tuesday, June 20, 2023 or at any postponement or adjournment thereof. Shares represented by this proxy will be voted in the manner directed by the stockholder. If no such directions are indicated, each of the Proxies will have authority to vote FOR the election of all nominees, and FOR proposals 2, 3 and 4. In his or her discretion, each of the Proxies is authorized to vote upon such other business as may properly come before the meeting. (Items to be voted appear on reverse side) C Non-Voting Items Change of Address — Please print new address below. Comments — Please print your comments below. +